PhD degree in Molecular Medicine
Curriculum in Molecular Oncology
European School of Molecular Medicine (SEMM)
University of Milan and University of Naples “Federico II”
Faculty of Medicine (MED/4)

in vivo shRNA screening to identify quiescence-related genes required for AML growth

Giulia De Conti
European Institute of Oncology (IEO), Milan
Student ID: R10310

Supervisor: Prof. Pier Giuseppe Pelicci
Added Supervisor: Dr. Emanuela Colombo

Academic year 2016-2017
# Table of Content

1. List of Abbreviations ................................................................. 4
2. Figures Index ............................................................................. 5
3. Tables index ................................................................................ 7
4. Abstract ...................................................................................... 8
5. Introduction .................................................................................. 9
   5.1 Hematopoiesis is hierarchically organized with HSCs at the apex .... 9
   5.2 Use of surface markers to identify HSCs .................................. 12
   5.3 Quiescence regulates HSCs self-renewal ............................... 13
   5.4 Acute Myeloid Leukemia ....................................................... 16
   5.5 Leukemia Stem Cells ............................................................. 21
   5.6 The AML cell of origin ........................................................... 23
   5.7 Clinical implication of LSCs .................................................... 24
   5.8 Targeting quiescence in LSCs ................................................ 26
   5.9 Pre-leukemic HSCs ................................................................. 29
   5.10 Assays to study HSCs and LSCs ............................................ 30
      5.10.1 Transplantation into immunodeficient mice ..................... 30
      5.10.2 Clonal tracking ............................................................... 31
   5.11 RNAi screenings ................................................................. 32
6. Materials and Methods .............................................................. 34
   6.1 AML mouse models .............................................................. 34
   6.2 Characterization of pre-leukemic transcriptional program .......... 36
      6.2.1 LT-HSCs RNA purification ............................................ 36
      6.2.2 Microarray analysis ......................................................... 36
   6.3 shRNA screening and clonal tracking ..................................... 37
<table>
<thead>
<tr>
<th>Section</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>6.3.1</td>
<td>Lentiviral libraries</td>
</tr>
<tr>
<td>6.3.2</td>
<td>Viral production and titration</td>
</tr>
<tr>
<td>6.3.3</td>
<td>Infection of AML blasts</td>
</tr>
<tr>
<td>6.3.4</td>
<td>Genomic DNA extraction and samples preparation for NGS</td>
</tr>
<tr>
<td>6.3.5</td>
<td>Preparation of NB4 spike-in control</td>
</tr>
<tr>
<td>6.3.6</td>
<td>NGS reads alignment</td>
</tr>
<tr>
<td>6.3.7</td>
<td>shRNA screening bioinformatics analysis</td>
</tr>
<tr>
<td>6.4</td>
<td>Limiting dilution transplantation assay</td>
</tr>
<tr>
<td>6.5</td>
<td>Validation experiments</td>
</tr>
<tr>
<td>6.5.1</td>
<td>Virus production</td>
</tr>
<tr>
<td>6.5.2</td>
<td>Blasts infection and sorting</td>
</tr>
<tr>
<td>6.5.3</td>
<td>RNA reverse-transcription and qPCR</td>
</tr>
<tr>
<td>6.5.4</td>
<td>Serial colony-forming-unit assay</td>
</tr>
<tr>
<td>6.5.5</td>
<td>Validation in vivo</td>
</tr>
<tr>
<td>7.</td>
<td>Aim of the project</td>
</tr>
<tr>
<td>8.</td>
<td>Results</td>
</tr>
<tr>
<td>8.1</td>
<td>NPMc+ and PML-RARα AML models are characterized by a prolonged pre-</td>
</tr>
<tr>
<td></td>
<td>leukemic phase</td>
</tr>
<tr>
<td>8.2</td>
<td>Gene expression profiles of pre-leukemic LT-HSCs showed an enforcement</td>
</tr>
<tr>
<td></td>
<td>of quiescent stem cell transcriptional program</td>
</tr>
<tr>
<td>8.3</td>
<td>NPMc+ and PML-RARα up-regulate a common set of quiescence genes in LT-</td>
</tr>
<tr>
<td></td>
<td>HSCs</td>
</tr>
<tr>
<td>8.4</td>
<td>The in vivo shRNA screening in NPMc+ and PML-RARα AML revealed</td>
</tr>
<tr>
<td></td>
<td>clonality issues</td>
</tr>
<tr>
<td>8.5</td>
<td>Clonal tracking experiments allow to study clonal growth in vivo</td>
</tr>
<tr>
<td>8.6</td>
<td>Spike-in to set a threshold for clone identification</td>
</tr>
</tbody>
</table>
8.7 Clonal tracking *in vivo* confirms clonal expansion during leukemia growth .....69
8.8 The MLL-AF9 driven AML model ...............................................71
8.9 The MLL-AF9 pre-leukemic LSK gene expression profile is enriched in quiescent stem cell signatures ..................................72
8.10 Clonal tracking and LIC frequency evaluation in MLL-AF9 leukemia ..........73
8.11 MLL-AF9 shRNA screening *in vivo* ............................................75
8.12 Identification of genes depleted during the *in vivo* screening ..................76
8.13 Candidate genes validation .................................................................82
8.14 Future plans .....................................................................................88
9. Discussion ............................................................................................89
10. References ............................................................................................94
### 1. List of Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Full Form</th>
</tr>
</thead>
<tbody>
<tr>
<td>5-FU</td>
<td>5-fluorouracil</td>
</tr>
<tr>
<td>AML</td>
<td>Acute Myeloid Leukemia</td>
</tr>
<tr>
<td>APL</td>
<td>Acute Promyelocytic Leukemia</td>
</tr>
<tr>
<td>BC</td>
<td>Barcode</td>
</tr>
<tr>
<td>BM</td>
<td>Bone Marrow</td>
</tr>
<tr>
<td>BM MNC</td>
<td>Bone Marrow Mono-Nucleated Cell</td>
</tr>
<tr>
<td>bp</td>
<td>Base pair</td>
</tr>
<tr>
<td>CMP</td>
<td>Common Myeloid Progenitor</td>
</tr>
<tr>
<td>CSC</td>
<td>Cancer Stem Cell</td>
</tr>
<tr>
<td>ELDA</td>
<td>Extreme Limiting Dilution Assay</td>
</tr>
<tr>
<td>FAB</td>
<td>French-American-British</td>
</tr>
<tr>
<td>FACS</td>
<td>Fluorescence-Activated Cell Sorter</td>
</tr>
<tr>
<td>FBS</td>
<td>Fetal Bovine Serum</td>
</tr>
<tr>
<td>FCS</td>
<td>Fetal Calf Serum</td>
</tr>
<tr>
<td>FDA</td>
<td>Food and Drug Administration</td>
</tr>
<tr>
<td>CML</td>
<td>Chronic Myeloid Leukemia</td>
</tr>
<tr>
<td>GFP</td>
<td>Green Fluorescent Protein</td>
</tr>
<tr>
<td>GMP</td>
<td>Granulocyte-Macrophage Progenitor</td>
</tr>
<tr>
<td>GSEA</td>
<td>Gene Set Enrichment Analysis</td>
</tr>
<tr>
<td>HSC</td>
<td>Hematopoietic Stem Cell</td>
</tr>
<tr>
<td>KI</td>
<td>Knock-in</td>
</tr>
<tr>
<td>KO</td>
<td>Knock-out</td>
</tr>
<tr>
<td>LDTA</td>
<td>Limiting Dilution Transplantation Assay</td>
</tr>
<tr>
<td>LIC</td>
<td>Leukemia Initiating Cell</td>
</tr>
<tr>
<td>Lin</td>
<td>Lineage markers</td>
</tr>
<tr>
<td>LT-HSC</td>
<td>Long Term-Hematopoietic Stem Cell</td>
</tr>
<tr>
<td>LSC</td>
<td>Leukemia Stem Cell</td>
</tr>
<tr>
<td>MOI</td>
<td>Multiplicity Of Infection</td>
</tr>
<tr>
<td>MPP</td>
<td>Multi Potent Progenitor</td>
</tr>
<tr>
<td>NGS</td>
<td>Next Generation Sequencing</td>
</tr>
<tr>
<td>NK</td>
<td>Normal Karyotype</td>
</tr>
<tr>
<td>PB</td>
<td>Peripheral Blood</td>
</tr>
<tr>
<td>PRKI</td>
<td>PML-RARα knock-in</td>
</tr>
<tr>
<td>qPCR</td>
<td>Quantitative Polymerase Chain Reaction</td>
</tr>
<tr>
<td>RBC</td>
<td>Red Blood Cell</td>
</tr>
<tr>
<td>RFP</td>
<td>Red Fluorescent Protein</td>
</tr>
<tr>
<td>RT</td>
<td>Room Temperature</td>
</tr>
<tr>
<td>shRNA</td>
<td>Short hairpin RNA</td>
</tr>
<tr>
<td>SPL</td>
<td>Spleen</td>
</tr>
<tr>
<td>ST-HSC</td>
<td>Short Term-Hematopoietic Stem Cell</td>
</tr>
<tr>
<td>TU</td>
<td>Transducing Unit</td>
</tr>
<tr>
<td>WHO</td>
<td>World Health Organization</td>
</tr>
<tr>
<td>WT</td>
<td>Wild-Type</td>
</tr>
</tbody>
</table>
2. Figures Index

Figure 1. The hierarchical organization of hematopoietic cells.................................10
Figure 2. Adult HSCs reside in specialized niches in the bone marrow.......................11
Figure 3. Redefined model for human hematopoietic system organization .................13
Figure 4. The two major models to describe tumor growth: stochastic vs hierarchical model..........................................................................................................................................................................................22
Figure 5. LSCs quiescence is regulated by intrinsic and extrinsic factors....................27
Figure 6. Map of Cellecta pRSI16 vector used for shRNA screenings.........................38
Figure 7. Map of Cellecta CellTracker™ Lentiviral Barcode vector used for clonal tracking experiments..........................................................................................................................................................................................39
Figure 8. Pre-leukemic and WT LT-HSCs are sorted from BM-MNCs.....................52
Figure 9. NPMc+ expression in LT-HSCs enforces a stem cell transcriptional program promoting quiescence .................................................................................................................................................................54
Figure 10. NPMc+ expression in LT-HSCs induces the up-regulation of self-renewal and quiescence genes..........................................................................................................................................................................................56
Figure 11. PML-RARα expressing LT-HSCs are enriched in stem cells and quiescence signatures.........................................................................................................................................................................................................................57
Figure 12. PML- RARα expression in LT-HSCs up-regulates quiescence genes...........59
Figure 13. NPMc+ and PML-RARα LT-HSCs up-regulate the same set of genes characteristic of quiescent HSCs .................................................................................................................................................................................................................60
Figure 14. Strategy for shRNA screen in vivo ................................................................62
Figure 15. Barcodes distribution is balanced in NPMc+ and PML-RARα reference samples (t0).........................................................................................................................................................................................................................63
Figure 16. Barcodes frequency distribution show a strong shift upon AML growth ....64
Figure 17. Few barcodes are highly expanded during in vivo screens with NPMc+ leukemia .................................................................................................................................................................................................................66
Figure 18. Spike-in control showed a linear relationship between the number of cells harboring a specific barcode and the NGS reads for the same barcode......69

Figure 19. Clonal tracking confirmed a strong clonal expansion during NPMc+ leukemia growth *in vivo* .................................................................70

Figure 20. Genes up-regulated by MA9 are enriched in NPMc+ and PML-RARα LT-HSCs gene expression profiles.................................................................73

Figure 21. MA9 leukemia grows in vivo without major clonal expansion .............74

Figure 22. Barcodes frequency distributions show a moderate shift during screening *in vivo* ..................................................................................................77

Figure 23. shRNAs have a similar distribution in the 6 screening replicates ..............78

Figure 24. Multi-dimensional scaling (MDS) plot show relationship between screening samples..........................................................................................79

Figure 25. shRNAs fold change distribution shows a number of depleted hairpins *in vivo* 80

Figure 26. Essential genes are scored as depleted by Roast gene set analysis ..........81

Figure 27. Depleted genes in common between the two analyses are selected for validation experiments..................................................................................82

Figure 28. shRNA-mediated gene silencing reduces colony-forming efficiency *in vitro* ...83

Figure 29. MA9 blasts infected with Brd4, Stat1 or Sytl4 shRNA are counter selected *in vitro* ..................................................................................................83

Figure 30. Brd4, Stat1 or Sytl4 down-regulation significantly delays MA9 leukemia burden ...................................................................................................84

Figure 31. MA9 blasts harboring Brd4 or Stat1 shRNA are counter selected during leukemia growth *in vivo* ...........................................................................85

Figure 32. MA9 blasts infected with Gfi1, Tie1 or Hoxa5 shRNA have decreased clonogenic potential in MC ...........................................................................86

Figure 33. Socs2 was efficiently down-regulated 72 hours after transduction.........87

Figure 34. Gfi1 and Tie1 were down-regulated 5 days after transduction ..............87
3. Tables index

Table 1. FAB classification of AML .................................................................17
Table 2. WHO classification of AML and related neoplasms .........................18
Table 3. Primers used to check oncogene expression via qPCR .......................36
Table 4. Genes targeted in M1 shRNA library ..............................................38
Table 5. Primers used for NGS library preparation ........................................43
Table 6. qPCR primers used to check gene silencing .....................................47
Table 7. NPMc+ expressing LT-HSCs up-regulated a set of quiescence positive regulators ........................................................................................................55
Table 8. PML-RARα LT-HSCs up-regulate a set of quiescence positive regulators ....58
Table 9. LIC frequency calculated by clonal tracking is affected by the low number of barcodes above the threshold ...........................................................................71
Table 10. MA9 LIC frequency calculation by limiting dilution ..........................75
4. Abstract

AML is hierarchically organized with at the apex Leukemia Stem Cells (LSCs), a rare cell population able to initiate and sustain the tumor growth. LSCs share many functional properties with normal Hematopoietic Stem Cells (HSCs) including self-renewal capacity and quiescence. Quiescent LSCs can survive to radiation and chemotherapy acting as a reservoir for leukemia relapse, the major cause of death for AML patients. Therefore, LSCs quiescence is critical for leukemia maintenance and few evidences suggest that quiescence regulation in pre-leukemic phase plays a pivotal role for leukemogenic process as well.

In this work, we demonstrated that the expression of NPMc+ or PML-RARα in HSCs is sufficient to enforce a quiescent stem cell gene expression profile. Therefore, we hypothesized that enhancement of the quiescent phenotype in HSCs could be a shared mechanism for leukemia development and maintenance. As an approach to examine the contribution of representative quiescence related genes in AML, we exploited RNA interference technology to perform in vivo screening. Among the target genes we found depleted during the screening, silencing of Stat1 or Sytl4 in AML blasts was sufficient to significantly decrease in vitro self-renewal and delay leukemia growth in vivo.
5. Introduction

5.1 Hematopoiesis is hierarchically organized with HSCs at the apex

The human body produces millions of blood cells every second for the entire lifetime\textsuperscript{1}. Since most of the various mature blood cells are short-lived, Hematopoietic Stem Cells (HSCs) have the role of continuously replenish multipotent progenitors and committed precursors in the process called hematopoiesis. HSCs are the rare cell population at the top of the well characterized hematopoietic hierarchy, which is depicted as a series of branches that become progressively restricted towards each hematopoietic lineage (Figure 1). As other stem cells, HSCs are able to self-renew and to differentiate, producing all the mature cells of the blood, both myeloid and lymphoid. Self-renewal is defined as the property of every stem cell to, upon division, produce one (asymmetric division) or two (symmetric division) daughter cells which retain the capacity for self-renewal, ensuring a long-term maintenance or expansion of the stem cell compartment.
Figure 1. The hierarchical organization of hematopoietic cells. In mice, the Lin- Sca1+ cKit+ compartment is enriched in stem and multipotent progenitor cells that gradually differentiates towards the hematopoietic lineages (adapted from Larsson and Karlsson, Oncogene 2005).

In mammals, the first “primitive” hematopoiesis wave arises from the yolk sac, followed by the aorta-gonad-mesonephros (AGM) region of the embryo, the fetal liver and, in the adult, HSCs reside in the bone marrow (BM). HSCs are highly dependent on their niche for the regulation of self-renewal and differentiation potential, and their properties may vary depending on the different environment. For instance, while adult HSCs are mostly quiescent, when in the fetal liver they are mostly proliferating, to ensure the stem cell expansion needed for embryogenesis. In the adult bone marrow, HSCs are found to reside in two distinct niches, the endosteal and the vascular region\textsuperscript{2-5} (Figure 2). Bone marrow cells synthetize important factors for HSCs such as thrombopoietin (TPO)\textsuperscript{6}, stem cell factor (SCF)\textsuperscript{7} and CXC-chemokine ligand 12 (CXCL12)\textsuperscript{8}. The niche microenvironment is therefore involved in HSCs quiescence and self-renewal control.
In homeostatic conditions, HSCs are mostly quiescent and only a small pool actively contributes to blood production. Quiescence is defined as the reversible absence of cycling, also named G0 phase of the cell cycle. The ability of HSCs to remain in the quiescent phase of the cell cycle is thought to be fundamental for stemness maintenance, even though a rapid cell cycle entry is required for the efficient response to conditions of hematopoietic stress such as bone marrow injury. In 1999, Weissman and colleagues analyzed the kinetics of the murine long-term HSCs (LT-HSCs) cell cycle demonstrating that, in homeostatic conditions, about 75% are in G0 phase and are recruited into cell cycle every 57 days, on average. More recent works confirmed these findings and computational models suggested that adult quiescent HSCs divide approximately five times during the mouse lifetime.

Stem cell quiescence is actively regulated by intrinsic mechanisms and microenvironmental signals, both converging towards characteristic transcriptional, epigenetic and metabolic profiles. Quiescence has been linked to HSCs long-term potential, necessary for the maintenance of blood compartment throughout the whole lifetime of an individual.
Functional HSCs maintain the capacity to rapidly enter cell cycle in response to physiological stresses such as blood loss. Loss of HSCs quiescence, as following hyper-proliferative signals, leads to depletion of HSCs pool, accumulation of DNA damage and exhaustion of self-renewal potential\textsuperscript{13,14}. Therefore, genes involved in quiescence regulation are critical for maintain self-renewal capacity in stem cells.

5.2 Use of surface markers to identify HSCs

In the last 30 years, many groups focused on the prospective isolation of HSCs. Florescence-activated cell sorting (FACS) technologies have improved the accuracy of single cell isolation according to surface markers expression or functional properties.

Thought the murine hematopoietic system has been more extensively characterized, it shares many critical features with the human, starting from the hierarchical organization. However, differences in the surface markers include the expression of the CD34 molecule that is exclusively present on human HSCs. Indeed, murine LT-HSCs are typically isolated using a combination of surface markers including Lin\textsuperscript{−}, Sca1\textsuperscript{+}, cKit\textsuperscript{+}, CD34\textsuperscript{−} and Flk2\textsuperscript{−} (Weissman approach) or Lin\textsuperscript{−}, Sca1\textsuperscript{+}, cKit\textsuperscript{+}, CD150\textsuperscript{+} and CD48\textsuperscript{−} (SLAM compartment)\textsuperscript{4,15}. More recently, highly quiescent LT-HSCs have been isolated as CD34\textsuperscript{−} Flk2\textsuperscript{−} cells within the SLAM compartment\textsuperscript{9}. Human HSCs, instead, have been historically described as enriched in Lin\textsuperscript{−}, Thy1\textsuperscript{+}, CD34\textsuperscript{+}, CD38\textsuperscript{neg/low} cells\textsuperscript{16}. More recently, Dick and colleagues described a combination of surface markers which is highly enriched in human functionally validated HSCs\textsuperscript{17} and includes Lin\textsuperscript{−}, Thy1\textsuperscript{+}, CD34\textsuperscript{+}, CD38\textsuperscript{−}, CD45RA\textsuperscript{−} and CD49f\textsuperscript{+}. Moreover, some functional properties can be used to enriched for HSCs, for instance the major efflux of Hoechst 3334 in the side-population\textsuperscript{18} or their enhanced label retaining properties, upon BrdU or H2B-GFP labeling\textsuperscript{9}.

Recent studies have challenged the traditional hierarchical organization of hematopoietic system\textsuperscript{19,20}. Dick and colleagues, combining single cell-sorting strategy and functional analysis, demonstrate that hematopoietic hierarchy might not follow the classical model. In
their model, oligopotent progenitors are the main component in the fetal liver hematopoiesis, while, in the adult BM, unilineage progenitors with myeloid or erythroid potential are prevalent. Human definitive hematopoiesis can be therefore subdivided in two main compartments with HSCs and MPPs at the top and committed unipotent progenitors at the bottom (Figure 3)\textsuperscript{19}.

**Figure 3. Redefined model for human hematopoietic system organization.** Recent studies demonstrated that adult hematopoiesis is mainly organized two compartment: a multipotent one formed by HSCs and MPPs and a unipotent compartment with lineages committed progenitors (adapted from Notta et al., Science 2016).

### 5.3 Quiescence regulates HSCs self-renewal

Every HSCs fate decision, such cell division, differentiation, migration, cell death or self-renewal, must be highly regulated to avoid HSCs exhaustion and bone marrow failure, on one side, and uncontrolled proliferation and leukemic transformation, on the other.

Cell cycle is mainly controlled by cyclins, cyclin-dependent kinases (CDKs) and their inhibitors (CKIs, CDK inhibitors). Several CKIs of either the INK4 or CIP/KIP gene families have been described to play a critical role in regulation of HSCs quiescence. p21 (Cdkn1a), is a CKI belonging to the CIP/KIP family and it is one of the major G1 phase checkpoint regulator. p21 knock-out (KO) mice show increased HSCs number and proliferation in homeostatic conditions. Upon myeloablative stress, such as 5-fluorouracil (5-FU) treatment, p21 KO mice die due to HSCs depletion. Furthermore, serial bone marrow transplantation (BMT) highlighted an impairment in self-renewal potential of p21 KO
Another member of the CIP/KIP family, p57 (Cdkn1c), is highly expressed in quiescent HSCs and progressively decreases during differentiation toward multipotent progenitors (MPPs). p57 deficient HSCs are less quiescent and are defective in self-renewal potential. Moreover, abnormalities in p57 KO HSCs can be corrected by knocking p27 (Cdkn1b), another CKI, in the p57 locus, suggesting a functional overlap between the two genes in control HSCs homeostasis.

Cdk6 promotes cell-cycle progression and has the opposite role of the above described CKIs. Cdk6 ablation does not affect HSCs in homeostatic conditions, yet Cdk6 KO HSCs can not be activated upon proliferation signals and do not efficiently repopulate mice in competitive BMT. Consistently, Cdk6 is non expressed in LT-HSCs, while it is present at high levels in short term-HSCs (ST-HSCs), where it may mediate rapid cell cycle entry upon stimulation. Thus, both LT- and ST-HSCs are quiescent, but the higher level of Cdk6 expression suggests that the ST-HSCs population is primed to enter proliferation. Enforced Cdk6 expression in LT-HSCs is sufficient to shorten quiescence exit without impact on functionality. Therefore Cdk6 absence preserve LT-HSC pool from exhaustion.

Cell cycle entry and quiescence of HSCs are also regulated by many transcription factors, including Gata2, Gfi1 and Cited2. Among them, Gata2 is highly expressed in quiescent hematopoietic cells and Gata2 KO mice die during embryonic development for defects in HSCs. Enforced GATA2 expression in human cord blood CD34+ cells increases quiescence but reduces proliferation and performance in long-term culture-initiating cell assay (LTC-IC). Indeed, human HSCs expressing high level of exogenous GATA2 fail to contribute to hematopoiesis in NOD-SCID mice while GATA2low cells delay hematopoiesis contribution, remaining quiescent. Therefore, Gata2 promotes quiescence both in vitro and in vivo and its expression must be fine tuned to maintain correct HSCs functionality.

Another factor involved in quiescence regulation is Gfi1, a zinc finger transcriptional repressor. Gfi1 KO mice show increased number of LT-HSCs in their bone marrow due to increased proliferation. Gfi1 KO HSCs, however, have decreased long-term reconstitution
capacity in competitive BMT, thus establishing an inverse correlation between HSCs proliferation and self-renewal potential\textsuperscript{28}.

Lastly, overexpression of the transcriptional coactivator CITED2 in human CD34\(^+\) cells resulted in enhanced HSCs colony-forming efficiency in vitro and a higher engraftment capacity in NSG mice. CITED2 enhances quiescence of CD34\(^+\)CD38\(^-\) HSCs, in part by increasing p21 expression\textsuperscript{29}.

Soluble factors and cytokines also play a role in HSCs quiescence regulations, pointing out the active and fundamental role of the niche microenvironment. Thrombopoietin (TPO) signaling, mediated by the interaction between TPO and its receptor MPL, is critical for maintaining quiescence and self-renewal in adult HSCs\textsuperscript{30}. HSCs that reside in the endosteal niche next to osteoblasts (which produce TPO) also express MPL. Inhibition of TPO/MPL signaling results in loss of quiescent HSCs while its activation results in p57 up-regulation\textsuperscript{6}.

Another example of environmental control of quiescence is the transforming growth factor-beta (TGF\(\beta\)), a secreted factor present at high levels in the bone marrow and a well described negative regulators of hematopoiesis. However, conditional deletion of TGF\(\beta\) receptor I (Tgfbr1) does not affect normal hematopoiesis and bone marrow cells are not defective in their ability to long-term repopulate recipient mice in serial BMT\textsuperscript{31}. Accordingly, in homeostatic conditions, TGF\(\beta\) signaling inhibition does not induce HSCs proliferation \textit{in vivo}. On the contrary, under stress conditions, such as treatment with chemotherapeutic agents, TGF\(\beta\) blockage accelerates hematopoietic reconstitution and delays HSCs re-enter in the G0 phase. p57 has been identified as one of the key downstream mediator of TGF\(\beta\)\textsuperscript{32}.

Furthermore, a recent work showed that TGF\(\beta\) is highly expressed by megacaryocytes (MK) in the bone marrow niche, and MK ablation results in HSCs exit from quiescence and increased proliferation. Indeed, Tgf\(\beta\)1 injection into mice depleted of MK is able to restore HSC quiescence while conditional deletion of Tgf\(\beta\)1 in MK phenocopies their complete ablation in the niche\textsuperscript{33}. 

15
Lastly, CXCR4, the receptor of CXCL12 chemokine, is present on HSCs and its deletion in adult mice results in HSCs reduction in number, increased sensitivity to myelotoxic stress such as 5-FU and disadvantage in competitive BMT. Moreover, deletion of Cxcl12 from mesenchymal cells in the niche is associated with marked loss of HSCs quiescence and long-term reconstitution ability.

Additionally, HSCs maintain the quiescence state by regulating specific metabolic pathways. Quiescent HSCs are characterized by a low mitochondrial activity and rely on glycolysis. HIF1α, the hypoxia inducible factor 1α, regulates HSCs in hypoxic conditions and promotes glycolysis. Indeed, HIF1α deficient HSCs lose their quiescence. More recently, dietary metabolites have been described to influence HSCs behavior. In particular, vitamin A, and its metabolite retinoic acid, have been linked to HSCs quiescence maintenance, while vitamin C signaling regulates HSCs self-renewal capacity.

### 5.4 Acute Myeloid Leukemia

Acute Myeloid Leukemia (AML) is a heterogeneous group of diseases characterized by immature and hyper-proliferating leukemic cells (i.e. leukemic blasts) infiltrating the bone marrow, blood and other tissues, eventually leading to hematopoiesis failure. Infiltration of the bone marrow and low number of normal terminally differentiated blood cells (anemia, neutropenia/lymphocytopenia and thrombocytopenia) are at the basis of the clinical manifestations of the disease, including fatigue, infections and hemorrhages, and, if not treated, AML has a rapid fatal outcome. AML is the most common type of a hematological malignancy in adults, with incidence increasing with age. In the United States, AML incidence ranges between 3-5 cases per 100,000 population. Only in 2016, about 20,000 new cases have been diagnosed and more than 10,000 patients died. Despite advances in therapies for some subtypes of AML and, in particular, for younger patients, prognosis for the majority of cases remain poor as only less than 50% of patients are definitely cured. The standard therapeutic approach, which has not significantly changed in the last 30 years,
consists in 7 days of cytarabine infusion and 3 days of anthracycline (e.g. doxorubicine), followed by allogeneic bone marrow transplantation for eligible patients. The induction therapy allows to rapidly reduce the number of blasts but the majority of patients undergoes relapse after initial remission\(^{42}\). This year, for the first time since 2000, a new drug, Midostaurin (Novartis), has been approved by FDA for the treatment of AML harboring mutations in FLT3 gene\(^{43}\).

The different AML types can be categorized using the French-American-British classification (FAB), established in 1976. It defines 8 classes of AML from M0 to M7 according to the morphological evaluation of the blasts (Table 1).

<table>
<thead>
<tr>
<th>Type</th>
<th>Name</th>
<th>Cytogenetics</th>
</tr>
</thead>
<tbody>
<tr>
<td>M0</td>
<td>Acute myeloblastic leukemia, undifferentiated</td>
<td></td>
</tr>
<tr>
<td>M1</td>
<td>Acute myeloblastic leukemia, without maturation</td>
<td></td>
</tr>
<tr>
<td>M2</td>
<td>Acute myeloblastic leukemia, with granulocytic maturation</td>
<td>t(8;21) RUNX1-RUNX1T1, t(6;9)</td>
</tr>
<tr>
<td>M3</td>
<td>Acute promyelocytic leukemia (APL)</td>
<td>t(15;17) PML-RARα, t(11;17)</td>
</tr>
<tr>
<td>M4</td>
<td>Acute myelomonocytic leukemia</td>
<td>inv(16), del(16q), t(16;16)</td>
</tr>
<tr>
<td>M5</td>
<td>Acute monocytic leukemia</td>
<td>t(9;11) MLLT3-KMT2A, t(11;19)</td>
</tr>
<tr>
<td>M6</td>
<td>Acute erythroid leukemia</td>
<td></td>
</tr>
<tr>
<td>M7</td>
<td>Acute megakaryoblastic leukemia</td>
<td>t(1;22)</td>
</tr>
</tbody>
</table>

**Table 1. FAB classification of AML.**

More recently, the World Health Organization (WHO) introduced a new classification, which incorporated additional disease features (genetic, morphological, immunophenotypic and clinical) and defined 6 AML subtypes\(^{44}\) (Table 2).
<table>
<thead>
<tr>
<th>Types</th>
<th>Genetic abnormalities</th>
</tr>
</thead>
</table>
| AML with recurrent genetic abnormalities | AML with t(8;21)(q22;q22); RUNX1-RUNX1T1  
AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11  
AML with PML-RARα  
AML with t(9;11)(p21.3;q23.3); MLLT3-KMT2A  
ML with t(6;9)(p23;q34.1); DEK-NUP214  
AML with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOM  
AML (megakaryoblastic) with t(1;22)(p13.3;q13.3); RBM15-MKL1  
AML with BCR-ABL1 (provisional entity)  
AML with mutated NPM1  
AML with biallelic mutations of CEBPA  
AML with mutated RUNX1 (provisional entity) |
| AML with myelodysplasia-related changes | Therapy-related myeloid neoplasms                                                                 |
| AML (not otherwise specified) | AML with minimal differentiation  
AML without maturation  
AML with maturation  
Acute myelomonocytic leukemia  
Acute monoblastic/monocytic leukemia  
Acute erythroid leukemia  
Pure erythroid leukemia  
Acute megakaryoblastic leukemia  
Acute basophilic leukemia  
Acute panmyelosis with myelofibrosis |
| Myeloid sarcoma | Transient abnormal myelopoiesis  
ML associated with Down syndrome |

### Table 2. WHO classification of AML and related neoplasms.

Accurate classification is fundamental for the proper diagnosis and treatment of the disease. Indeed, in combination with other prognostic factors such as the age, different AML subtypes are associated with different clinical outcome. The broad spectrum of chromosomal aberrations and mutations described in different AML allows the stratification into favorable, intermediate and adverse risk groups. In particular, translocations t(8;21) and t(15;17), which cause the expression of the oncogenes AML1-ETO and PML-RARα respectively, are indicative of favorable prognosis. Complex karyotype and monosomy are instead associated with poor prognosis due to high treatment failure risk. Finally, AML
without cytogenetic abnormalities (NK-AML, normal-karyotype), accounting for about 50% of all AML cases, often falls into the intermediate risk group. Among NK-AML, gene mutations are fundamental to refine risk stratification. Mutations in CEBPA or NPM1 without concomitant mutation in FLT3 are associated with good prognosis, while mutations in KMT2A, DNMT3A or FLT3 itself are associated with worse prognosis.

One of the major obstacles in leukemia eradication is given by the extensive genomic and biological inter- and intra-tumoral heterogeneity. Extensive whole-exome sequencing experiments showed that each AML presents about 10 mutations per exome, yet more than a hundred of different genes were found to be recurrently mutated in AML patients. AML intra-tumoral complexity is a well described phenomenon characterized by the presence of multiple genetic subclones within the leukemic bulk, which contributes to therapy failure and relapse, the major cause of death in leukemia patients.

Mutations in the NPM1 gene are found in 55% of NK-AML (which account for 45% of all AML cases). In the WHO classification, NPM1-mutated AML are recognized as a distinct category while, in the FAB classification, NPM1 mutations are associated with most subtypes except the M3. NPM1 gene encodes for nucleophosmin, a nucleus-to-cytoplasm shuttling protein. Mutations in NPM1, mainly found in exon 12, cause a frame shift in the C-terminus, which generate a new nuclear export signal and is associated with protein delocalization in the cytoplasm (NPMc+). The most common mutation consists in a 4 base pair insertion (type A mutation) and is found in about 80% of cases. Despite NPM1 mutations were discovered more than 10 years ago, the associated molecular mechanisms are still unclear. Available data suggest that NPMc+ posses both loss- and gain-of-functions. In murine models, expression of NPMc+ alone is not sufficient to induce leukemia, suggesting that cooperative mutations are needed. Indeed, internal tandem duplication (ITD) of the FLT3 gene, which encode for a receptor tyrosine kinase, is frequently associated with NPMc+ in AML, suggesting genetic cooperation between the two mutations. Notably, the variant allele frequency (VAF) of NPMc+ in AML is around 0.5.
while that of FLT3-ITD is much lower, indicating that only NPMc+ is present in heterozigosity in all cells of the samples, thus suggesting that the NPMc+ occurs prior to FLT3-ITD during leukemogenesis\textsuperscript{53}. NPMc+ is also found in association with DNMT3A, IDH1, IDH2 and TET2, while it is mutually exclusive with chromosomal translocations (including PML-RAR\textalpha and MLL-AF9) and mutations in MLL1, RUNX1, CEBPA and TP53\textsuperscript{54,55}. Comparative analysis of the gene expression profile of NPMc+ and NPM1-WT AML allowed the identification of a NPMc+ associated signature characterized by down-regulation of CD34 and up-regulation of HOX, MEIS1 and PBX3 genes, which are known master regulators of HSCs self-renewal\textsuperscript{56,57}.

Acute promyelocytic leukemia (APL) is a distinct subtype of AML, accounting for 5-15\% of all adult AML and characterized by a block of myeloid differentiation at the promyelocyte stage. Almost all patients harbor a translocation between chromosome 15 and 17 that leads to the formation of the oncogenic fusion protein PML-RAR\textalpha\textsuperscript{58}. PML-RAR\textalpha transgenic mice develop APL after a long latency (6-12 months) and at variable penetrance, suggesting that PML-RAR\textalpha needs secondary events to induce a full-blown leukemia\textsuperscript{59-61}. Indeed, several and different additional genetic alterations (e.g. FLT3, WT1, NRAS and KRAS) have been described both in human and in murine APL\textsuperscript{47,62-65}. Beyond genetic complexity, combinatorial treatment with all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) is one of the best example of targeted therapy in cancer.

Treatment with ATRA and ATO induces disease remission in the vast majority of APL patients, suggesting that PML-RAR\textalpha expression is indispensable for the maintenance of the disease. Indeed, both agents induce PML-RAR\textalpha degradation and restoration of the normal PML and RAR\textalpha signaling, resulting in blasts maturation\textsuperscript{66}. Notably, treatment with ATRA or ATO alone is invariably associated with disease relapse, frequently due to somatic mutations in PML-RAR\textalpha, PML or RAR\textalpha, while ATRA-ATO combination induces disease cure, suggesting that the two agents target PML-RAR\textalpha in different cellular compartment of the leukemia\textsuperscript{67}. 
Rearrangements of MLL gene (KMT2A or MLL1) occur in about 10% of human AML. The MLL gene is located on chromosome 11 and it encodes for a H3K4 methyl-transferase mainly acting as a transcriptional activator. More than 50 translocation partner genes have been described in AML patients and among them, MLL-AF4, MLL-AF9, MLL-ENL, MLL-AF10 and MLL-AF6 are the most frequent. MLL-fusion proteins retain the functional N-terminal of MLL, fused to the C-terminal of the translocation partner. All the MLL-fusion genes are in frame and result in the expression of chimeric transcription factors capable of efficient transformation of HSCs and progenitor cells. Critical transcriptional targets of the MLL-fusion proteins are the HOX cluster, MEIS1 and PBX3 regulators of HSCs self-renewal, CDK6, JMJD1C, MEF2C, EYA1, MYB and MECOM.

5.5 Leukemia Stem Cells

Only a fraction of leukemic cells is able to sustain the tumor growth. These cells share morphological and biological features with normal HSCs, and are termed Leukemia Stem Cells (LSCs). LSCs are experimentally defined by their ability to: (1) generate a xenograft resembling the original tumor, (2) self-renew, assessed by serial passages in vivo, and (3) give rise to daughter cells, which can proliferate but are unable to establish or maintain leukemia in vivo (i.e. non-LSCs).

Seminal discoveries in AML in the 90s allowed the more general conception of the Cancer Stem Cell (CSC) model, which is today used to explain relevant features of the intra-tumor biological heterogeneity of both leukemia and epithelial tumors. According to the CSC model, tumors are described as aberrant tissues harboring their own hierarchical organization, similar to that of their normal counterparts, with CSCs placed at the apex of the hierarchy. In this view, CSCs are considered the only cell type which possesses self-renewal properties and the intrinsic ability to perform asymmetric cell divisions, thus being responsible for both tumor growth and generation of intra-tumoral cell
heterogeneity\textsuperscript{82,83} (Figure 4, right panel). Accordingly, CSCs are regarded as responsible for tumor initiation, maintenance, propagation and disease relapse after initial remission. Although the CSC model is widely accepted within the scientific community, most currently used therapeutic approaches target highly proliferating cells and find their rationale on a different model of tumorigenesis, the so-called “stochastic model” of tumor growth, which implies that all cancer cells have equal self-renewal ability and tumorigenic potential (Figure 4, left panel). However, in both models, intra-tumoral heterogeneity is generated by the acquisition of novel somatic mutations that establish subclonal populations within the tumor. Hierarchically-organized tumors show an additional degree of intra-tumoral heterogeneity due to phenotypic transition between CSCs and non-CSCs. This plasticity has been well described in solid tumors and is highly dependent on microenvironmental stimuli\textsuperscript{84}.

![Figure 4. The two major models to describe tumor growth: stochastic vs hierarchical model.](image)

In the left panel is depicted the stochastic model of tumor organization in which each tumor cell has the same capability to growth. On the right, the hierarchical cancer organization is depicted: in this model, CSCs are the only cells able to self-renew and sustain the tumor growth. Nevertheless, a certain grade of plasticity can occur (dashed arrow). In both models, the acquisition of novel somatic mutations account for the genetic heterogeneity within the tumor (adapted from Beck and Blanpain, Nat Rev Cancer 2013).

Traditional chemo- and radiotherapies, which are able to target only actively cycling cells, have limited or no effects on LSCs. This intrinsic resistance can be due to the prevailing quiescent state of LSCs, and other mechanisms, such as the expression of drug efflux pumps, anti-apoptotic mediators and peculiar DNA damage repair response\textsuperscript{85}. Thus, development of
novel therapeutic strategies aimed at targeting quiescent LSCs may impact on leukemia eradication.

Pioneering studies in John Dick’s lab demonstrated the existence of LSCs in human AML by the prospective isolation and xenotransplantation into immunocompromised mice of different leukemic populations based on CD34 and CD38 antigen expression. The first studies showed that only the CD34⁺CD38⁻ compartment retains tumorigenic ability in vivo. Nevertheless, there is great heterogeneity in the expression level of the two surface markers among different AML samples. Indeed, further studies identified LSCs at varying frequencies in different cell populations and, for instance, in NPM-mutated AML, LSC activity is commonly found in the CD34⁻ compartment. More recently, Dick and colleagues, combining deep sequencing and xenotransplantation, demonstrated that LSCs can either express HSCs/progenitors markers or be enriched in immunophenotypically committed cells. Notably, regardless their immunophenotype, functionally validated LSCs are characterized by the same transcriptional program strongly related to stemness maintenance.

5.6 The AML cell of origin

Cancer development was initially described as the accumulation of sequential somatic mutations in a cell clone. If these mutations result in a growth advantage, the clone becomes the predominant cell population. This simplistic model has been intensively revised over years. For many cancer types, including AML, the target cell of the transformation events is still not clear. The findings that AML blasts can co-expresses both myeloid and lymphoid markers and the observation that the only cells capable of transplanting leukemia in xenograft models have a CD34⁺CD38⁻ phenotype, similar to that of normal human HSCs, lead to hypothesize that the cell of origin resides in this compartment. However, LSCs do not necessarily originate from the malignant transformation of normal HSCs. Indeed, xenotransplantation experiments in later studies led to the detection of LSCs in AML
populations with variable phenotypes downstream of HSCs. In the case of APL, the PML-RARα fusion gene is absent in HSCs compartment while is found in more committed progenitors (i.e. promyelocytes) which are able to engraft in humanized ossicle xenograft mice\textsuperscript{91,92}. Moreover, studies on murine models of spontaneous leukemogenesis have shown that oncogenic mutations can also confer self-renewal properties to cells with limited regenerative potential\textsuperscript{93-95}.

A recent study showed that the AML chromatin landscape pattern is able to reflect the transformed cell of origin, offering a new prognostic tool for patients\textsuperscript{96}. Indeed, it is worth thinking that the biological properties of LSCs, then, may vary with regard to the immunophenotype, transcriptome, genetics, cell cycle status and multilineage potential of the cell of origin, as shown for other tumors, such as lymphoma\textsuperscript{97,98}.

5.7 Clinical implication of LSCs

Beside the cellular origin, the existence of LSCs has important implications for treatment, since these cells seem to be intrinsically resistant to traditional therapies, thus preventing disease eradication. Moreover, especially in AML, high LSCs frequency and better engraftment ability in immunodeficient mice are associated with more aggressive disease\textsuperscript{99,100}. As well, the degree of overlap between LSCs and HSCs gene expression profiles correlates with poor clinical outcome\textsuperscript{101}. In the last years, many groups tried to identify expression signatures able to classify AML according to their pathogenesis and prognosis\textsuperscript{102}. In particular, Ng and colleagues have recently published a biomarker list of 17 genes related to stemness (the LSC17 score), differentially expressed between LSCs and non-LSCs, across 78 AML patients. The LSC17 score proved to be able to identify patients with poor outcomes in five independent patient cohorts belonging to different AML subtypes\textsuperscript{103}.

The ability of LSCs to survive chemotherapy and radiotherapy has been associated with functional properties and molecular mechanisms shared with normal HSCs, such as
quiescence\textsuperscript{104,105}, apoptosis evasion\textsuperscript{106}, enhanced DNA damage response\textsuperscript{107} and lower concentration of reactive oxygen species (ROS)\textsuperscript{108}. Quiescence, in particular has been linked to therapy resistance since the traditional therapies are usually specific for actively proliferating cells. Notably, cell cycle-restriction appears to be fundamental for leukemia development\textsuperscript{107}. High-throughput analysis of neutral somatic mutations (i.e. microsatellite instability) at single cell level allowed the reconstruction of cell lineage trees in two AML patients, from diagnosis to relapse. These cell lineage trees showed that mutations present in minor slowly-cycling sub-clones were maintained after treatment and, suggesting that AML relapse can derive from rarely-dividing cells capable of surviving chemotherapy. Interestingly, this phenomenon was not observed in other hematological malignancies such as Acute Lymphoid Leukemia (ALL)\textsuperscript{109}. Quiescent cells are characterized by low oxidative phosphorylation and LSCs have been shown to have lower ROS levels and oxygen consumption rates. At the same time, LSCs are highly dependent on oxidative phosphorylation, becoming more sensitive to Bcl-2 inhibitors\textsuperscript{106,108}. Bcl-2 inhibitors are currently in clinical trials for hematological malignancies including AML.

Despite the many common features between LSCs and HSCs, it may be possible to target gene networks that are specific for the survival of LSCs. This is the case of miR-126, which was found to promote quiescence and increased self-renewal in primary LSCs, with an opposite function in HSCs\textsuperscript{110}. The design of novel therapeutic strategies for AML treatment should therefore include the specific targeting of LSCs, while sparing normal HSCs.

Since markers commonly used to study LSCs in human AML are based on the immunophenotype of normal hematopoietic cells, a lot of effort has been invested into identifying specific molecules that discriminate LSCs from both normal HSCs and the bulk of leukemic blasts. Many surface markers have been proposed to be specific for LSCs in different AML subtypes but they often allow only the partial identification of the LSCs pool.

The CD33 antigen, for instance, is highly expressed in AML blasts and in normal human myeloid committed progenitors, while it is not expressed on normal HSCs\textsuperscript{111}. Therefore,
CD33 is a potential target for new therapies and specific antibodies are currently in clinical trials. In particular, GO (Gemtuzumab Ozogamicin), an anti-CD33 monoclonal antibody conjugated to the toxin calicheamicin, gave significantly increased remission rates in advanced and relapsed APL\textsuperscript{112,113}. Since GO is highly active against APL, as compared to other AMLs, APL stem cells may reside in the CD33\textsuperscript{+} compartment and possess a more mature phenotype\textsuperscript{114}. However, in 2010 Pfizer voluntarily withdrew GO due to safety concerns and the drug is currently available only for palliative use. SGN-CD33A, a novel anti-CD33 antibody conjugated to two molecules of a pyrrolobenzodiazepine dimer drug, is currently in clinical trials for AML and, up to now, it has demonstrated anti-leukemic activity with 47\% of complete remission and rapid blast clearance with relatively modest toxicity\textsuperscript{115}.

5.8 Targeting quiescence in LSCs

Inducing LSCs to proliferate might appear as a counterintuitive anti-leukemic strategy, because of the risk to accelerate disease progression or new mutations accumulation. However, experimental treatments with agents that induce cell cycle entry, in combination with standard chemotherapy, did not show evidences of accelerated disease progression\textsuperscript{116,117}. Moreover, since quiescence regulation is similar in normal HSCs, this waking strategy could affect normal hematopoiesis. Yet, clinical studies in hematological malignancies have not reported excessive toxicity, suggesting that a therapeutic window exists to distinguish normal and leukemic stem cells, at least for some neoplasms\textsuperscript{118}. Thus, elucidation of the molecular mechanisms underlying maintenance of quiescence in LSCs might be critical for the identification of novel drug targets. Many approaches directed to target quiescence in LSCs have been described in Chronic Myeloid Leukemia (CML) in which LSCs phenotype is well characterized as CD34\textsuperscript{+}CD38\textsuperscript{−}.
Figure 5. LSCs quiescence is regulated by intrinsic and extrinsic factors (adapted from Takeishi and Nakayama, Cancer Science 2016).

As already mentioned, self-renewal and quiescence of LSCs and HSCs is regulated by cell-autonomous mechanisms and microenvironment signals (Figure 5). Among the known cell autonomous regulators of LSCs quiescence is the promyelocytic leukemia protein (PML), first identified as a component of the PML–RARα fusion protein in patients with APL (reviewed in Mazza and Pelicci, 2013). It has been demonstrated that ATO triggers proteasome-dependent PML-RARα degradation and reactivation of PML signaling, leading to LSCs eradication. ATO is also effective in the treatment of CML, where like PML inactivation, it reduces the proportion of quiescent LSCs. The mechanisms by which PML regulates quiescence may involve metabolic processes, in particular fatty acid oxidation, and cell cycle control via regulation of p21, cyclins, and c-Myc.

As above-mentioned, the CKI p27 is necessary for HSCs quiescence maintenance. At the same time, p27 deletion in MLL-AF9 blasts reduces LSCs frequency and, inducing proliferation, it causes loss of drug resistance. Another transcriptional regulator involved in quiescence regulation is the peroxisome proliferator-activated receptor-γ (PPARγ), a
nuclear receptor that governs fatty acid storage and glucose metabolism. The PPARγ agonist pioglitazone induces cell cycle entry of LSCs isolated from CML patients, an effect that was associated with down-regulation of STAT5 and CITED2\textsuperscript{124}. The combination of pioglitazone and Imatinib (Novartis) reduces LSCs viability \textit{in vitro} and a phase II clinical trial in CML is currently ongoing\textsuperscript{125}.

Among enzymatic functions, the F-box protein FBXW7, the substrate recognition subunit of the SKP1-CUL1-FBXW7 ubiquitin-ligase complex, has been described to regulate LSCs quiescence. The SKP1-CUL1-FBXW7 ubiquitin-ligase complex is responsible for the ubiquitination and subsequent degradation of many cellular substrates including c-Myc. In a mouse model of CML, Fbxw7 genetic ablation induces LSCs to enter cell cycle due to increased expression of c-Myc\textsuperscript{126}. Moreover, Fbxw7-deficient LSCs become sensitive to Ara-C and Imatinib treatment leading to CML eradication. Another pathway tightly regulated in LSCs biology is mTOR. mTORC1 inhibition, as induced by rapamycin treatment, is sufficient to decrease LSCs number in a Pten-depleted AML model. Moreover, rapamycin treatment is able to restore HSCs function in the same context\textsuperscript{127}. Though the mTORC2 complex is not extensively characterized, it has been recently demonstrated that depletion of one of its component, namely Rictor, leads to hyperactivation of mTORC1 and MLL-AF9 LSCs exhaustion after serial BMT, due to quiescence exit\textsuperscript{128}.

Regarding the extrinsic factors regulating LSCs quiescence, treatment with the granulocyte colony-stimulating factor (G-CSF), a cytokine that promotes maturation, differentiation and proliferation of myeloid cells, has been shown to induce LSCs cell cycle entry. G-CSF treatment in combination with Ara-C is able to reduce LSCs frequency improving survival in AML xenograft models\textsuperscript{105}. Chemokine ligand 12 (CXCL12) is a chemoattractive cytokine with the function of retaining HSCs in the BM and maintain their quiescence, interacting with its receptor CXCR4 present on HSCs surface\textsuperscript{8}. Targeting this axis with CXCR4 inhibitors is sufficient to sensitize AML and CML cells to chemotherapy\textsuperscript{129-131}. Other microenvironment signals important for LSCs are the interferons (IFN), cytokines mainly
produced by cells of the immune system in response to infections and also tumor cells. In particular, IFNα treatment in CML patients is able to potentiate Imatinib therapy, though the underlying molecular mechanisms are not clear. The effect of INFα treatment is instead well describe in normal HSCs where it induces cell cycle entry associated with down-regulation of p27, p57, Foxo3a and TGFβ, all genes that support HSCs quiescence. Lastly, angiopoietin-1 (Ang1) is a cytokine known to promote HSCs quiescence via the interaction with its tyrosine-kinase receptor Tie2. Ang1 signaling pathway has been recently described as a mechanism of quiescence maintenance in Evi1 highly expressing AML, protecting leukemic cells from anti-cancer drugs.

Growing evidences showed that also noncoding RNAs play important role in stem cell maintenance. microRNAs are small non-coding RNA molecules regulating gene expression at post-transcriptional level. For instance, miR-99 family consists of a group of microRNA highly expressed in HSCs and in acute myeloid LSCs. miR-99 promotes in vitro clonogenic capacity both in HSCs and LSCs, while its down-regulation reduces HSCs long-term reconstitution ability inducing cell cycle entry, and it reduces LSCs frequency in a MLL-AF9 driven AML mouse model by inducing blasts differentiation.

5.9 Pre-leukemic HSCs

With the advent of massive sequencing technologies, lots of information have been produced on the mutational status of both normal and malignant hematopoiesis. High-throughput sequencing of AML samples showed that mutations such as DNMT3A, IDH2 or TET2, found at diagnosis are often present in patients at complete morphological remission. Moreover, investigation of residual normal HSCs in AML samples revealed that many patients harbor a population of HSCs bearing some of the mutations present in the corresponding leukemic cells. This so-called pre-leukemic stem cells are present both at diagnosis and relapse and their proportion in the stem cell compartment correlates with poor prognosis. This finding is clinically relevant because relapses could arise both through
selection of pre-existing and resistant leukemic clones or through the evolution of pre-leukemic HSCs through the acquisition of additional mutations. In the last scenario, pre-leukemic HSCs will act as a reservoir for leukemic progression and they should be carefully evaluated during minimal residual disease monitoring.

Pre-leukemic mutations have been found in healthy individuals as well. On average, clonal hematopoiesis, as identified by a somatic mutation, is observed in 10% of healthy individuals older than 65 years old\textsuperscript{143}. A more recent study, able to detect very low frequent mutations (0.0003 VAF) in the peripheral blood of 50-60 years-old healthy individuals, indicates that the 95% of them is characterized by clonal hematopoiesis, frequently harboring mutations in DNMT3A and TET\textsuperscript{2}\textsuperscript{144}. Moreover, mutations are present in multiple hematopoietic lineages, suggesting a long lived progenitor or a HSC as the cell of origin. Clonal hematopoiesis is associated with higher risk of hematological cancer development\textsuperscript{143,145}. In contrast to leukemic cells, pre-leukemic cells are not characterized by aberrant self-renewal or differentiation potential and they require additional mutation to establish a frank leukemia.

\section*{5.10 Assays to study HSCs and LSCs}

\subsection*{5.10.1 Transplantation into immunodeficient mice}

Traditionally, HSCs functionality is assayed by transplantation of defined cell populations into irradiated recipient mice. In this setting, it is possible to dissect all the defining functions of stem cells, namely engraftment, self-renewal, bone marrow reconstitution and multi-lineage differentiation. Transplantation experiments, coupled with cell purification based on surface marker expression, have been instrumental for the characterization of HSCs and progenitors. As for normal HSCs, the study of LSCs depends and is influenced by the available experimental assays. The gold standard for human LSCs identification, in fact, remains transplantation into immunocompromised mice. However, xenotransplantation assay can introduce bias due to interspecies difference in cytokines, microenvironment and
immune system interactions$^{146}$. Various xenograft models are suitable for the engraftment of self-renewing leukemia cells. Cells that are able to propagate leukemia in this context are functionally defined as Leukemia Initiating Cells (LICs), and they correspond to the experimental definition of LSCs$^{147}$. Although, however, in vivo transplantation provided the first evidence for the existence of LSCs, this assay has some technical limitations. In particular, leukemogenic potential cannot be assessed at single cell level and LSCs potential can be just segregated to a previously defined cell compartment. In addition, cells able to initiate the disease in mice could not be the same cells responsible for leukemia growth and maintenance in the patients. This problem is highlighted by the fact that the same leukemic population shows variable engraftment potential in different mouse strains: the more immunodeficient the mice are, the more they are permissive to human leukemic cells growth. Indeed, the transition from athymic mice, which lacked T-lymphocytes, to the SCID (severely combined immunodeficient) strains, which also lacke B-lymphocytes, allowed the first AML engraftment, and the introduction of more immunodeficient models (e.g. NOD or NSG mice, which also have defective innate immune system), as well as strains engineered to express human cytokines, led to significantly higher sensitivity in xenotransplantation assays$^{148,149}$. 

5.10.2 Clonal tracking

It has been recently shown that unperturbed native hematopoiesis differs from post-transplantation hematopoiesis$^{150,151}$. Single HSC reconstitution capacity, including self-renewal and differentiation, has been studied by lineage-tracing and clonal tracking experiments in mice. In vivo genetic lineage-tracing experiments are based on the expression of an inducible recombinase under the control of a stem cell-restricted gene (e.g. TIE2), which activates a stable reporter gene (e.g. YFP) in HSCs selectively, thus allowing their identification and tracing$^{150}$. Lineage tracking experiments have been also conducted using inducible transposons, which allow in situ HSCs tagging without manipulation (such as
isolation, \textit{ex vivo} transduction and transplantation in irradiated mice)\textsuperscript{151}. Results obtained with these more physiological settings are consistent with model in which adult hematopoiesis is maintained by thousands of clones derived from long-lived multipotent progenitors, rather than from HSCs.

On the other hand, clonal tracking experiments combine viral cellular barcoding and NGS allowing an accurate investigation of HSCs clonal expansion \textit{in vivo}\textsuperscript{152,153}. These experiments, based on barcoded HSCs transplantation in irradiated recipient mice, showed that HSCs contribute at different extent to hematopoiesis and more than one HSCs population exists with distinct lineage bias\textsuperscript{153}. HSCs heterogeneity is well characterized in terms of lineage bias and proliferative kinetics, especially during aging when the HSCs pool increases in size and accumulates preferentially myeloid-biased stem cells with reduced self-renewal potential\textsuperscript{154}.

As well as for normal hematopoiesis, clonal tracking strategy can be used to map leukemic cell kinetics \textit{in vivo}. Lentiviral barcoding of leukemic blasts and transplantation in recipient mice allow the quantification of LIC frequency and the evaluation of leukemia clonal composition\textsuperscript{155}. Beside LIC frequency estimation, clonal tracking experiments allow to study the heterogeneous proliferative capacity of single LICs as well as drug resistance mechanisms, as already described in solid tumors\textsuperscript{156}. Moreover, it has an increased sensitivity because it allows single cell identification by detection of individual barcodes.

### 5.11 RNAi screenings

RNA interference (RNAi) was originally discovered in \textit{C. elegans} in 1998\textsuperscript{157} and it rapidly became a broadly used tool for loss-of-function studies, both \textit{in vitro} and \textit{in vivo}\textsuperscript{158,159}. RNAi screens exploit a physiological mechanism that represses gene expression, primarily by causing the degradation of mRNA transcripts, allowing to interrogate the function of several genes simultaneously\textsuperscript{160}. For a successful screen several factors have to be carefully evaluated such as library size, coverage and target identification and validation approaches.
RNAi library can be organized either in array format, in which each RNAi molecule is individually tested, or in a pool of shRNA (short hairpin RNA) molecules simultaneously assayed. The combination of this approach with retro- or lentiviral vectors allowed the possibility to perform screening in primary mammary cells, including stem cells. Indeed, several groups have performed RNAi screen in normal HSCs leading to new insights on self-renewal regulation\textsuperscript{161-164}. Other groups have employed this tool to identify hematological disease-relevant genes, especially tumor-suppressors as in the case of Rad17 in Eμ-Myc lymphoma model\textsuperscript{165}. Finally, several RNAi screens have been performed to identify potential therapeutic target in hematological malignancies. One of the best example is the work of Zuber and colleagues, in which they used a murine AML model, characterized by the expression of MLL-AF9 and Nras\textsuperscript{G12D} oncogenes, to perform an \textit{in vitro} RNAi screen targeting around 250 chromatin regulators\textsuperscript{166}. The study lead to the identification of Brd4, a bromodomain protein which binds to acetylated histones regulating transcription, as necessary for leukemia maintenance, sustaining Myc expression. They also demonstrated that the Brd4 small molecule inhibitor JQ1 has an anti-leukemic effect \textit{in vitro} and \textit{in vivo}, establishing the basis for its clinical usage. The MLL-AF9 leukemia mouse model has been successfully used to identify other potential therapeutic targets via \textit{in vivo} screens. In particular, Ebert’s group identified Itgb3 and Csnk1a1 as conceptually ideal targets because dispensable for normal HSCs but required for AML \textit{in vivo}\textsuperscript{167,168}. Beyond studies on normal and malignant hematopoietic systems, the use of similar screening approaches has been extensively used in various solid tumors, leading to the identification of genes involved in the tumorigenic process\textsuperscript{169,170}. 

33
6. Materials and Methods

6.1 AML mouse models

Mice were housed in a pathogen-free animal facility at European Institute of Oncology. The procedures related to animal use have been communicated and have been approved by the Italian Ministry of Health.

NPMc+ transgenic mouse model express the cDNA of the most frequent NPM mutation (mutA, found in about 80% of the patients)\(^{50}\) into the Hprt locus and under the control of the pCAG promoter\(^{171}\). These mice express the oncogene upon CRE-mediated excision of the STOP cassette cloned between the pCAG promoter and the NPMc+ cDNA. Conditional NPMc+ mice were crossed with conditional Rosa26-EYFP mice\(^{172}\) to obtain NPMc+\(^{1}\)\^{}\(^{0}\)\^{}\/{YFP}\(^{0}\)\^{}\- mice. In order to express the oncogene, bone marrow mononucleated cells (BM MNCs), isolated from NPMc+\(^{1}\)\^{}\(^{0}\)\^{}\/{YFP}\(^{0}\)\^{}\ or YFP\(^{0}\)\^{}\- mice, were treated \textit{ex vivo} with TAT-CRE, a recombinant version of CRE recombinase fused with the HIV protein TAT. In details, total BM cells were isolated by grinding bones from posterior limbs and sternum. Total BM cells were layered onto density gradient (Histopaque® 1083, Sigma-Aldrich) and centrifuged at 1500 rpm, 45 min at 4°C. During centrifugation, BM MNCs remain at the PBS-Histopaque® interface and can be collected. BM-MNCs were re-suspended 5x10\(^{6}\)/ml in serum-free media (HyClone, USA) and incubated for 45 min at 37°C with 100 µg/ml of TAT-CRE. Transduction was stopped diluting samples with 10 volumes of BM-MNCs medium (IMDM (Gibco/Invitrogen, Carlsbad, CA), 12.5% heat inactivated fetal bovine serum (FBS), 12.5% Horse serum, 1% L-glutamine, 100 ng/ml SCF, 20 ng/ml IL3, and 20 ng/ml IL6 (PeproTech), 0.1% β-mercaptoethanol, and Hydrocortisone 10 ng/ml), cells were spun down, re-suspended in BM-MNCs medium and cultured at a density of 2x10\(^{6}\) cells/ml for 48 hours. YFP+ cells were FACS sorted and intravenously injected into lethally irradiated (7.5 Gy) C57 BL/6 Ly5.1 recipient mice. Mice transplanted with NPMc+ expressing BM-
MNCs develop leukemia after a long latency (median 564 days) and with low penetrance (33%)\(^1\).

For the PML-RAR\(\alpha\) leukemia model, we backcrossed the mCG-PR knock-in (KI) mice, provided by Tim Ley\(^6\), in the C57 BL/6J strain. These mice expressed the PML-RAR\(\alpha\) oncogene in stem and early myeloid cells under the control of the murine cathepsin G promoter. Mice develop spontaneously a disease resembling the human APL, with 70% penetrance at 6-16 months of age (median 10 months). Murine APL can be serially injected in C57 BL/6 Ly5.1 recipient mice.

MLL-AF9 leukemia was generously provided by Dr Chi Wai So. Leukemia was obtained by MSCV-MLL-AF9-puro retroviral transduction and transformation assay (RTTA) of cKit+ cells isolated from BM-MNCs, as previously described\(^1\). In brief, cKit+ BM cells were FACS isolated from wild-type C57 BL/6 Ly5.1 mice, transduced by spinoculation with the retroviral vector expressing the MLL-AF9 oncogene, and serially re-plated in methylcellulose medium prior to injection into sub-lethally irradiated (5 Gy) C57 BL/6J recipient mice. Mice die of leukemia approximately one month after injection.

Murine AML were characterized based on blasts immunophenotype and oncogene expression. Mice were sacrificed at the first signs of pain and leukemic blasts were isolated from spleen and bone marrow after centrifugation through a Histopaque\® gradient, stained with fluorochrome-conjugated antibodies against myeloid and lymphoid markers and analyzed by FACS. NPMc+ expression was assessed by western blot and immunofluorescence analysis as described in Mallardo et al., 2013. Quantitative polymerase chain reactions (qPCR), from blasts isolated from leukemic spleen, were performed according to standard techniques using primers specific for PML-RAR\(\alpha\) cDNA (Table 3). Blood smears were stained with May-Grünwald-Giemsa while bone marrow/spleen paraffin embedded samples were stained with haematoxylin-eosin, according to standard protocols, and used for AML diagnosis.
### Table 3. Primers used to check oncogene expression via qPCR.

<table>
<thead>
<tr>
<th>Primer name</th>
<th>Sequence 5’→3’</th>
</tr>
</thead>
<tbody>
<tr>
<td>PR forward</td>
<td>AGGGACCCTATTGACGTTGAC</td>
</tr>
<tr>
<td>PR reverse</td>
<td>ACAGACAAAGCAAGGCTTGTAG</td>
</tr>
<tr>
<td>mTBP forward</td>
<td>TAATCCCAAGCGATTTGCTG</td>
</tr>
<tr>
<td>mTBP reverse</td>
<td>CAGTTGTCCGTGGCTCTCTT</td>
</tr>
</tbody>
</table>

**6.2 Characterization of pre-leukemic transcriptional program**

**6.2.1 LT-HSCs RNA purification**

NPMc+ pre-leukemic and wild-type LT-HSCs were purified from mice injected with NPMc+fl/fl/YFPfl/fl or YFPfl/fl recombined BM-MNCs, 4 months after transplantation. PML-RARA pre-leukemic and wild-type LT-HSCs were purified from the bone marrow of 10-12 weeks old mice. BM-MNCs were isolated as previously described and stained with fluorochrome-conjugated antibodies against Sca1, c-Kit, Flk-2, CD34 and the lineage markers antibodies cocktail (Lin: B220, Ter-119, CD3, Mac1, Gr1, CD4 and CD8), all provided by eBioscience. LT-HSCs were then sorted via FACS as Lin-, Sca1+, cKit+, CD34- and Flk-2- and RNA was immediately extracted with the PicoPure™ RNA Isolation Kit (ThermoFisher), according to manufacturer protocol. The integrity of RNA was analyzed by Bioanalyzer (Agilent).

**6.2.2 Microarray analysis**

RNA purified from WT and pre-leukemic LT-HSCs was analyzed on Affymetrix GeneChip® Mouse Gene 2.0 ST array. Double stranded cDNA synthesis was performed with Nugen® Pico WTA Systems V2 (NuGEN Technologies, Inc.). Microarray raw data were normalized by RMA using Partek Genomic Suite 6.6. A set of differentially expressed genes between pre-leukemic and WT samples was identified by applying a threshold of FC>|1.5| and FDR<0.1. Gene set enrichment analysis (GSEA, v2.14 software Broad Institute)\(^\text{174}\) was used to investigate whether a gene set was significantly over-represented in
the transcriptome of the pre-leukemic cells. The curated gene sets collection (c2.all.v5.1.symbols.gmt) was downloaded from MSigDB. Moreover, three custom gene sets related to quiescence have been tested for enrichment. A gene set was identified as significantly enriched when associated with FDR q-val<0.1. A detailed description of the GSEA methodology and interpretation is provided at http://www.broadinstitute.org/gsea/doc/GSEAUserGuideFrame.html.

For microarrays validations qPCR reactions, 10 ng of total RNA purified from WT or pre-leukemic LT-HSCs was reverse-transcribed using Super Script IV (Invitrogen). cDNA was pre-amplified with TaqMan® PreAmp Master Mix Kit and then amplified using pre-designed TaqMan Gene expression assays (Thermo Fisher Scientific). All experiments were run in triplicate and results normalized to Gapdh and Gusb mRNA expression level.

### 6.3 shRNA screening and clonal tracking

#### 6.3.1 Lentiviral libraries

The custom shRNA library used for the in vivo screenings was purchased from Cellecta Inc. In the pRSI16 lentiviral vector, shRNAs are cloned under the control of the U6 promoter and univocally associated with a 22-nucleotides barcode (BC). The vector also encodes for the puromycin resistance (PuroR) and the Red Fluorescence Protein (TagRFP) reporter gene, under the control of the UbiC promoter (Figure 6). The shRNA library (M1) contains 1,000 different shRNAs targeting 96 genes (about 10 shRNAs/gene), including 4 controls (Table 4). The control library is composed of 1,200 different 22-nucleotides BCs cloned in the same vector.
Figure 6. Map of Cellecta pRSI16 vector used for shRNA screenings.

<table>
<thead>
<tr>
<th>Genes targeted in M1 shRNA library</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abcb1b, Acox1, Adcy9, Adgrg1, Adipor2, Adssl1, Angpt1, Anxa4, Atxn11, Bach1, Bgn, Brd4, Cables1, Cbfa2t3, Cdkn1a, Chmb1, Cited2, Creg1, Csgalnae1, Ctxa2a, Cyp4v2, Dcaf11, Dock9, Dusp6</td>
</tr>
</tbody>
</table>
For the clonal tracking experiments, we purchased a lentiviral library containing two consecutive 18-nucleotides barcodes for a total complexity of about $30 \times 10^6$ different barcodes combinations (CellTracker™ Lentiviral Barcode Library, Cellecta Inc). The lentiviral backbone encodes for the PuroR and the TagRFP genes under the control of the UbiC promoter (Figure 7).

![Figure 7. Map of Cellecta CellTracker™ Lentiviral Barcode vector used for clonal tracking experiments.](image)

6.3.2 Viral production and titration

For lentiviral production, the 2nd generation packaging vectors pMD2.G and pCMVdR8.2 were used. 293T cells were transfected with Lipofectamine® and PLUS® reagents (ThermoFisher), according to manufacturer protocol. In brief, 293T were plated in 15 cm dishes in DMEM (Lonza), 2 mM L-glutamine, 100 U/ml penicillin/streptomycin, 10% Fetal Bovine Serum (FBS) and transfected when 70% confluence was reached. We mixed the library DNA and the packaging vectors DNA with the PLUS® reagent in 1.2 ml of serum-free Opti-MEM™: 6 µg library DNA, 7 µg pMD2.G, 24 µg pCMVdR8.2 and 60 µl PLUS®,
per dish. In an other tube we mixed 90 µl Lipofectamine® with 1.2 ml of serum-free OptiMEM™, per dish. Both solutions were incubated separately for 15 min at room temperature (RT) and then mixed together. After another 15 min incubation at RT, the DNA-Lipofectamine® mixture was added to the 293T dish. We usually transfct 10 293T 15 cm dishes, as suggested by Cellecta guidelines, in order to cover library complexity and obtain a high viral titer. Medium containing lentiviral particles was collected 24, 48 and 72 hours after transfection, replacing with fresh medium. Lentiviral supernatant was filtered through a 0.2 µm Nalgene™ Rapid-Flow™ Sterile Disposable Filter Unit (ThermoFisher), concentrated by ultracentrifugation at 24000 rpm, 2h at 4°C with a Optima L-90K ultracentrifuge (Beckman Coulter) and stored at -80°C. Lentiviral titer was evaluated by transducing 0.1x10⁶ 293T/well in 6 wells plate with serial dilution of the viral stock. 72h after infection, 293T were harvest and analyzed by FACS for the percentage of TagRFP+ cells. Viral titer, measured as transducing units per ml (TU/ml), was calculated with the following formula:

\[
titer \left( \frac{TU}{ml} \right) = \frac{\text{number of target cells} \times (0.1 \times 10^6) \times \% \text{TagRFP positive cells}}{\text{volume of virus added} \ (ml)}
\]

6.3.3 Infection of AML blasts

Leukemic blasts are maintained in Iscove’s Modified Dulbecco’s Medium (IMDM, Lonza), 2 mM L-glutamine, 15% Fetal Calf Serum (FCS), 15% 5637-conditioned medium and 25% WEHI-3B-conditioned medium. Blasts are infected with lentiviral particles by spinoculation with MOI=3 at 2300 rpm, for 90 min at RT. For shRNA screenings, 24-50x10⁶ blasts/well were plated in 6 wells RetroNectin®-coated plates in presence of 4 mg/ml of polybrene. For clonal tracking experiments, 1x10⁶ blasts/well were plated in 24 wells RetroNectin® (Takara)-coated plates in presence of 4 mg/ml of polybrene. In order to dilute polybrene, 2 hours after spinoculation, one volume of fresh medium was added to each well. 24 hours
after transduction, half of the blasts was collected and froze as reference starting point (t0) and the remaining cells were intravenously injected in recipient mice. Transduction efficiency was measured by FACS analysis of TagRFP positive cells, 72 hours after transduction.

6.3.4 Genomic DNA extraction and samples preparation for NGS
Both for screening and clonal tracking experiments, leukemic blasts were harvested from spleen and bone marrow of moribund mice. Genomic DNA was isolated by phenol/chloroform extraction as follow: cells were resuspended in 5-10 ml P1 buffer with RNAse A (Qiagen) and 0.5% SDS and incubated 5 min at RT. The resuspension volume depends on the amount of cells. For clonal tracking experiments, NB4 spike-in cells were added prior to phenol/chloroform extraction. One volume of phenol:chloroform:isoamyl alcohol 25:24:1 (Sigma Aldrich) was added to cell suspension and the mix was vigorously vortexed and centrifuged at 4200 rpm for 2h at RT. The upper phase was collected and washed with an additional volume of chloroform (VWR). DNA precipitation was performed adding 1 volume of isopropanol (Panreac AppliChem) and 0.125 volumes of 3M sodium acetate to the upper phase. After over night incubation, the mixture was spun at 4200 rpm for 1h at RT. DNA pellet was then washed with 10 ml ethanol 70%, spun at 4200 rpm 10 min at RT and air-dried. DNA was finally dissolved in nuclease-free water and quantified by NanoDrop ND-100 (Thermo Fisher).

According to Cellecta guidelines, libraries for NGS were prepared using all the genomic DNA extract from each sample, in order to ensure the complete representation of the barcodes. The strategy foresees two nested PCR with primers designed to include the sequencing adapters needed for Illumina HiSeq 2000 flow cell clustering. In the first PCR, DNA barcodes are amplified from the total genomic DNA while, in the second PCR, a sampling of the 1st reaction is used to remove non-specific PCR products and excess genomic DNA. For all reactions, Titanium® Taq DNA polymerase (Takara) was used because very
efficient in amplify high amount of DNA. The 1st PCR reaction was prepared as following: 25 µg genomic DNA, 0.3 µM of each primer, dNTPs 200 µM, 1x Titanium® Taq Buffer, 0.5 U Titanium® Taq DNA polymerase, in a final volume of 100 µl per tube. The 1st PCR program is:

<table>
<thead>
<tr>
<th>Temperature</th>
<th>Time</th>
<th>Cycles</th>
</tr>
</thead>
<tbody>
<tr>
<td>94°C</td>
<td>3 min</td>
<td>1</td>
</tr>
<tr>
<td>94°C</td>
<td>30 sec</td>
<td></td>
</tr>
<tr>
<td>60°C</td>
<td>10 sec</td>
<td>16</td>
</tr>
<tr>
<td>72°C</td>
<td>20 sec</td>
<td></td>
</tr>
<tr>
<td>68°C</td>
<td>2 min</td>
<td>1</td>
</tr>
</tbody>
</table>

After the 1st PCR round, all reactions from the same sample were combined together and 5 µl of the first amplification were used for the 2nd PCR with primers containing P5 and P7 adapter sequences. The 2nd PCR reaction was prepared as following: 5 µl 1st PCR, 0.5 µM of each primer, dNTPs 200 µM, 1x Titanium® Taq Buffer, 0.5 U Titanium® Taq DNA polymerase, in a final volume of 100 µl. The 2nd PCR program is:

<table>
<thead>
<tr>
<th>Temperature</th>
<th>Time</th>
<th>Cycles</th>
</tr>
</thead>
<tbody>
<tr>
<td>94°C</td>
<td>3 min</td>
<td>1</td>
</tr>
<tr>
<td>94°C</td>
<td>30 sec</td>
<td></td>
</tr>
<tr>
<td>65°C</td>
<td>10 sec</td>
<td>16</td>
</tr>
<tr>
<td>72°C</td>
<td>20 sec</td>
<td></td>
</tr>
<tr>
<td>68°C</td>
<td>2 min</td>
<td>1</td>
</tr>
</tbody>
</table>

Due to differences in the shRNA and clonal tracking vectors, specific primers are used during barcodes amplification (Table 5). 10 µl of the 2nd PCR was run on a 3% agarose gel to confirm the correct size of the amplicons: 251 bp for M1 and 1.2k libraries and 267 bp for clonal tracking library. PCR products were purified with QIAquick PCR purification kit (Qiagen) following the manufacturer’s protocol and quantified by Qubit™ dsDNA HS Assay Kit (Thermo Fisher). DNA libraries were sequenced on Illumina HiSeq 2000 sequencing platform, with 51 bp single-end reads, using the GexSeq sequencing primer. 20-40 million reads were generated for each sample. The original Cellecta strategy does not
allow to insert any index during library preparation, therefore it was not possible to sequence more samples in the same lane of the flow cell. To overcome this important limitation, we modified primers used in the second PCR in order to insert different 6 bp indexes. With this optimization and a specific bioinformatics pipeline we were able to sequence up to 5 samples in the same lane.

<table>
<thead>
<tr>
<th>Primer name</th>
<th>Sequence 5’→3’</th>
<th>Use</th>
</tr>
</thead>
<tbody>
<tr>
<td>F2</td>
<td>TCGGATTTCGCCACCAAGCACCGCTA</td>
<td>shRNA 1st PCR</td>
</tr>
<tr>
<td>R2</td>
<td>AGTAGCTGAAGAGCAGAGAA</td>
<td>shRNA 1st PCR</td>
</tr>
<tr>
<td>Gex1_NF2</td>
<td>CAAGCAGAAGACGGCATACGATCGCACCAGCACGCTACGCA</td>
<td>shRNA 2nd PCR</td>
</tr>
<tr>
<td>Gex2_NR2</td>
<td>AATGATACGGCGACCAGCAGCAGGAACAAACGAGA</td>
<td>shRNA 2nd PCR</td>
</tr>
<tr>
<td>Gex1_2</td>
<td>CAAGCAGAAGACGGCATACGATACATCGCGCACCAGCACGCTACGCA</td>
<td>shRNA 2nd PCR (index2)</td>
</tr>
<tr>
<td>Gex1_4</td>
<td>CAAGCAGAAGACGGCATACGATATTGTCACCAGACAGCACGCTACGCA</td>
<td>shRNA 2nd PCR (index4)</td>
</tr>
<tr>
<td>Gex1_6</td>
<td>CAAGCAGAAGACGGCATACGATATTGTCACCAGACAGCACGCTACGCA</td>
<td>shRNA 2nd PCR (index6)</td>
</tr>
<tr>
<td>Gex1_7</td>
<td>CAAGCAGAAGACGGCATACGATATTGTCACCAGACAGCACGCTACGCA</td>
<td>shRNA 2nd PCR (index7)</td>
</tr>
<tr>
<td>Gex1_12</td>
<td>CAAGCAGAAGACGGCATACGATATTGTCACCAGACAGCACGCTACGCA</td>
<td>shRNA 2nd PCR (index12)</td>
</tr>
<tr>
<td>FwdHTS3</td>
<td>TCGGATTTCGACAAAGACGGCATACGATACATCGCGCACCAGCACGCTACGCA</td>
<td>clonal tracking 1st PCR</td>
</tr>
<tr>
<td>R2</td>
<td>AGTAGCTGAAGAGCAGAGAA</td>
<td>clonal tracking 1st PCR</td>
</tr>
<tr>
<td>Gex1_Bpi</td>
<td>TCAAGCAGAAGACGGCATACGATACGATACATCGCGCACCAGCACGCTACGCA</td>
<td>clonal tracking 2nd PCR</td>
</tr>
<tr>
<td>P5_NR2</td>
<td>AATGATACGGCGACCAGCAGCAGGAACAAACGAGA</td>
<td>clonal tracking 2nd PCR</td>
</tr>
<tr>
<td>GexSeq</td>
<td>AGAGGTTCAGAGAGTCTACAGTCCGAA</td>
<td>NGS primer</td>
</tr>
</tbody>
</table>

Table 5. Primers used for NGS library preparation.

6.3.5 Preparation of NB4 spike-in control

We selected independent clones from a DNA library containing 13,000 different barcodes (Cellecta, Inc.). This library differs from the CellTracker™ library for the barcode structure, indeed it contains just a single barcode of 18 bp. Since the two libraries are cloned in the same lentiviral backbone, barcodes can be amplified with the same PCR strategy, described in section 6.3.4. Single barcodes were selected by bacterial transformation and isolation of single colonies. Plasmidic DNA isolated from bacteria was analyzed by Sanger sequencing to confirm the presence of a single barcode and used to produce lentiviral particles, as
described in section 6.3.2. NB4 cells were transduced at low MOI with each barcode to ensure the presence of single integrant per cells. Infected cells were selected with 1 µg/ml puromycin for 48 hours and defined numbers of NB4 cells clones were combined to prepare the spike-in control for clonal tracking experiments.

6.3.6 NGS reads alignment

FASTQ files were prepared from the sequencing runs to count the number of reads per barcode. For each sample, reads were aligned to the respective reference sequences (1.2k or M1 library) using the Bowtie aligner\textsuperscript{175} and by considering only those reads having, at most, three mismatches for each alignment. Barcodes frequency was calculated by normalizing each barcode read count on the total number of aligned reads. For subsequent analysis, fold change was calculated as the ratio of barcodes reads between the spleen and the reference samples, either for 1.2k and M1 screening samples.

For clonal tracking experiments, barcodes reads were perfect match aligned to the reference library using the Bowtie aligner. Spike-in reads were aligned with the same procedure to the known barcode sequences. All read counts were normalized based on the total number of reads per sample and frequency distribution was calculated.

6.3.7 shRNA screening bioinformatics analysis

In order to identify depleted genes during the screening we developed two distinct bioinformatics approaches. ECDF analysis: we summed the 1.2k FC distributions to obtain a unique empirical cumulative distribution function (ECDF). The empirical distribution function is an estimate of the cumulative distribution function that generated the points in the sample; specifically, the cumulative distribution function (CDF) of a real-valued random variable X, or just distribution function of X, evaluated at x, is the probability that X will take a value less than or equal to x. Therefore, by mean of resulting ECDF from 1.2k samples, we calculated an empirical pValue for each shRNA present in M1 samples. We
then aggregate these shRNA pValues among sample replicates with Fisher’s Method in order to obtain a FC, a pValue and a qValue for each shRNA. With the purpose of define enriched and depleted genes, we evaluated how many depleted shRNAs we would find by recursively 1000 random picking 10 shRNAs, regardless the gene they target. One gene can be considered depleted if at least 5 out of 10 hairpins are significantly depleted, with 95% confidence. The threshold for significant enrichment is instead of at least 4 out of 10 shRNAs.

EdgeR analysis: EdgeR package was developed for RNAseq analysis but it can be used as well for shRNA screening statistical analysis176. Prior to proceed, samples were adjusted to account for differences in library size. In particular, TMM normalization was applied on counts and then a multidimensional scaling (MDS) plot was generated to assess the consistency between replicate samples. The barcodes variability was estimated under the assumption that common dispersion across barcodes is flat and the more the barcodes are present, the lower dispersion we have. Samples were analyzed by fitting a generalized linear model (GLM). We first analyzed the changes in barcodes abundance during the 1.2k screening to set a threshold for enrichment/depletion analysis in M1 screening. Statistical testing for changes in barcodes abundance between spleens and reference samples was carried out using exact test that allow results to be ranked by significance. We then applied the significance thresholds calculated on 1.2k control samples, to the shRNAs of M1 samples. Finally, since 10 hairpins per gene are present, we used Roast, a gene set analysis tool, to obtain a gene-by-gene ranking, rather than a shRNA specific one.

### 6.4 Limiting dilution transplantation assay

For the limiting dilution transplantation assay, MLL-AF9 cells, freshly isolated from moribund mice, were intravenously injected (from $5 \times 10^5$ to 100 cells per mice) into sub-lethally irradiated (5 Gy) C57 BL/6 J recipient mice, with $2 \times 10^5$ splenocytes as carrier. LIC frequency was measured used ELDA software177.
6.5 Validation experiments

6.5.1 Virus production

Single shRNA targeting candidate genes were cloned in the same lentiviral vector used for the screening (pRSI16, see section 6.3.1). We used empty vector and shRNA directed against Luciferase as controls. Lentiviral particles were produced transfecting 293T cells with shRNA plasmid and 2nd generation packaging vectors, as reported in section 6.3.2.

6.5.2 Blasts infection and sorting

MA9 blasts were maintained in Iscove’s Modified Dulbecco’s Medium (IMDM, Lonza), 2 mM L-glutamine, 15% Fetal Calf Serum (FCS), 15% 5637-conditioned medium and 25% WEHI-3B-conditioned medium. 20x10^6 blasts/well were plated in 6-wells RetroNectin®-coated plates and infected with single shRNA lentiviral particles by spinoculation at 2300 rpm, for 90 min at RT, in presence of 4 mg/ml of polybrene. 2 hours after spinoculation, one volume of fresh medium was added to each well. Transduction efficiency was measured by FACS analysis 72 hours after transduction and infected blasts were sorted as TagRFP+ cells using MoFlo® Astrios™ cell sorter (Beckman Coulter).

6.5.3 RNA reverse-transcription and qPCR

RNA was extracted from TagRFP+ sorted cells using PicoPure™ RNA Isolation Kit (ThermoFisher), according to manufacturer protocol. 0.1-1 µg of total RNA was reverse-transcribed using ImProm-II™ Reverse Transcriptase kit (Promega). RNA was first incubated with random primers (0.5 µg/reaction) at 70°C for 15 min and then immediately on ice. The following mix was then added:
ImProm-II™ 5X reaction buffer 10 µl
MgCl₂ 25 mM 5 µl
dNTPs (10 mM each) 2.5 µl
recombinant RNAse inhibitor 1.5 µl
ImProm-II™ Reverse Transcriptase 1 µl
Nuclease-free water to 50 µl

Reaction was incubated at 42°C for 70 min and then at 70°C for 15 min. cDNA was stored at -20°C.

For gene expression analysis, qPCR was performed using 10 ng of cDNA, 0.2 µM of both primers and 10 µl of FAST SYBR™ Green Master Mix, AmpliTaq® Fast DNA Polymerase (ThermoFisher) in a final volume of 20 µl per reaction in 96-well plate. Fluorescence accumulation during qPCR reaction was detected on CFX96 Touch™ Real-Time PCR Detection System (Biorad). Relative mRNA quantification was performed by the comparative ΔΔCt method using Tbp for normalization. Primers used are listed in Table 6.

<table>
<thead>
<tr>
<th>Primer name</th>
<th>Sequence 5’→3’</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brd4 forward</td>
<td>AAAACTCCAACCCCGATGAG</td>
</tr>
<tr>
<td>Brd4 reverse</td>
<td>GAACCCAGCAATACGTCAC</td>
</tr>
<tr>
<td>Stat1 forward</td>
<td>GCCGAGAAACATACCAGAGAATC</td>
</tr>
<tr>
<td>Stat1 reverse</td>
<td>GATGTATCCAGTTGCTTAGGG</td>
</tr>
<tr>
<td>Syt4 forward</td>
<td>AATGGTGAGGCTGGAAG</td>
</tr>
<tr>
<td>Syt4 reverse</td>
<td>ACCACTTCGCCATTACTGATC</td>
</tr>
<tr>
<td>Socs2 forward</td>
<td>TGAAGCATGAGCCTTTCCTC</td>
</tr>
<tr>
<td>Socs2 reverse</td>
<td>GCAGACACTGTACCCAC</td>
</tr>
<tr>
<td>Gfi1 forward</td>
<td>TGGAGCAACACAAGGCAG</td>
</tr>
<tr>
<td>Gfi1 reverse</td>
<td>AGTACTGACAGGGATAGGGG</td>
</tr>
<tr>
<td>Tie1 forward</td>
<td>CCAGTGCCAGTGTCAAATG</td>
</tr>
<tr>
<td>Tie1 reverse</td>
<td>CCTATGTTGAACTCCACCTCTG</td>
</tr>
<tr>
<td>Hoxa5 forward</td>
<td>CAAGCTGCACATTAGTCAC</td>
</tr>
<tr>
<td>Hoxa5 reverse</td>
<td>GGTAAGGGTGAAGATGGGAT</td>
</tr>
<tr>
<td>Tbp forward</td>
<td>TAATCCCAAGCGATTTGCTG</td>
</tr>
<tr>
<td>Tbp reverse</td>
<td>CAGTTGTCCGTGGCTCCTTT</td>
</tr>
</tbody>
</table>

Table 6. qPCR primers used to check gene silencing.
6.5.4 Serial colony-forming-unit assay

500 TagRFP+ sorted MA9 blasts were plated in MethoCult M3434 (StemCell Technologies) in 35 mm dish. 7 days after plating, colony formation was quantified. For serial passages, 500 cells of each replicate were used for subsequent plating in MethoCult M3434.

6.5.5 Validation in vivo

2x10^5 TagRFP+ sorted MA9 blasts were intravenously injected in sub-lethally irradiated C57 BL/6 J 8-12 weeks old mice (3-4 mice/group). Latency in leukemia development was monitored and mice were sacrificed when moribund, according to animal facility guidelines. Leukemic infiltration was assessed in peripheral blood, spleen and bone marrow by measuring by FACS the percentage of TagRFP+ cells over the total CD45.1+ population.
7. Aim of the project

Chemotherapy-resistant AML cells are thought to be enriched in quiescent LSCs and several publications highlighted the importance of quiescence for AML maintenance. However, additional studies are required to define the role of quiescence and underlying mechanisms during LSCs selection and leukemia development.

Our lab had previously demonstrated that cell cycle restriction is critical in preventing excess DNA-damage accumulation and functional exhaustion of LSCs in PML-RARα and AML1-ETO driven leukemia\(^\text{107}\). Moreover, NPMc+ expression in normal bone marrow is able to expand the LT-HSCs number without depleting the pool of quiescent LT-HSCs, therefore preserving their functionality (unpublished results).

We decided to investigate if induction of HSCs quiescence is a distinctive property of AML-associated oncogenes, the role of HSCs quiescence during the leukemogenic process, and if HSCs quiescence is required for LSCs maintenance of leukemia outgrowth. Therefore, the general aim of my thesis project is to investigate whether oncogene-induced pathways controlling HSCs quiescence, as identified in pre-leukemic cells, are also critical for the retention of LSCs self-renewal capacity and ultimately for leukemia maintenance. As experimental approach, we decided to take advantage of RNA interference technology to perform \textit{in vivo} screenings to identify genes that could be required for the maintenance of AML. In particular, the specific aims of the project are:

1. To obtain gene expression profiles of pre-leukemic HSCs expressing different AML initiating oncogenes, namely NPMc+ and PML-RARα.

2. To identify common pathways enriched in the pre-leukemic transcriptional profiles, with a particular focus on stemness- and quiescence-related genes.

3. To select \(~100\) quiescence-related genes induced by the leukemic oncogenes in pre-leukemic HSCs to design a low complexity shRNA library.
4. To perform *in vivo* shRNA screening on NPMc+ and PML-RARα driven murine AML samples.

5. To develop a bioinformatics pipeline to identify genes significantly depleted or enriched during the screening in order to proceed with validation experiments *in vitro* and *in vivo*.

Employing this strategy on a number of leukemia characterized by different genetic alterations, we aimed at identifying not only genes fundamental for a single subtype but to discover key genes common to several AML, which may offer new therapeutic strategies in a wide group of patients.
8. Results

8.1 NPMc+ and PML-RARα AML models are characterized by a prolonged pre-leukemic phase

As model system, we started our investigation with two AML mouse models characterized by the expression of the cytoplasmic mutant of NPM1 (NPMc+) or the fusion proteins PML-RARα. In both model systems, leukemia recapitulates the main features of the corresponding human diseases and develops after a prolonged pre-leukemic phase.

NPMc+ transgenic mice harbor the cDNA of the most frequent NPM1 mutation (mutA, found in about 80% of the patients) which is expressed upon CRE-mediated excision of the floxed STOP cassette present between the promoter and the NPMc+ cDNA. Oncogene expression can be tracked in situ thanks to the co-expression of NPMc+ and the yellow florescent protein (YFP) (see Materials and Methods, section 6.1). Bone marrow mononucleated cells (BM-MNCs) isolated from NPM1c+/YFP control mice (YFP) were treated ex vivo with the recombinant TAT-CRE protein and FACS-sorted in YFP+ and YFP- subpopulations. Notably, NPMc+ is expressed only in the YFP+ population, with a recombination efficiency of ~85%, assessed by immunofluorescence (unpublished, not shown). BM MNCs expressing NPMc+ are transplanted in irradiated syngeneic recipient mice which develop leukemia with low penetrance (33.3%) and long latency (median 564 days). PML-RARα transgenic mice harbor the cDNA of the fusion protein targeted into the murine cathepsin G locus. These mice express constitutively low level of PML-RARα in HSCs and progenitors, and develop leukemia with high penetrance (90%) and 10 months median latency.

Thus, both NPMc+ and PML-RARα oncogenes are sufficient to initiate the leukemogenic process but require other genetic lesions for the full expression of a leukemia phenotype. Indeed, the two models are characterized by a prolonged phase whereby oncogenes are
expressed in an otherwise normal bone marrow. During the pre-leukemic phase, the organization of the hematopoietic tissue is near identical to that of normal mice, thus allowing direct comparison of identical cell types, such as the HSCs, and unambiguous identification of de-regulated gene expression. Given the long latency we observed prior of leukemia development, we were able to evaluate early perturbation occurring upon oncogene expression in normal hematopoietic cells, in order to define critical mechanisms during the leukemogenic process.

8.2 Gene expression profiles of pre-leukemic LT-HSCs showed an enforcement of quiescent stem cell transcriptional program

To investigate the transcriptional changes induced by oncogene expression in HSCs, we performed global gene expression analysis of LT-HSCs, purified as Lin-, Sca1+, cKit+, CD34- and Flk2- cells, from NPMc+ and PML-RARα pre-leukemic mouse models. Sorting strategy is depicted in Figure 8. LT-HSCs NPMc+/YFP+ or YFP+ have been isolated 4 months after BMT while LT-HSCs PML-RARα or WT have been isolated from 10-12 weeks old mice.

**Figure 8. Pre-leukemic and WT LT-HSCs are sorted form BM-MNCs.** Representative FACS plot of sorting strategy used to isolate both WT and pre-leukemic LT-HSCs. LSK (Lin’, Sca1’, cKit’) population was gated within the lineage negative cells. LT-HSCs were gated as CD34-, Flk2- cells within the LSK population.
RNA was extracted just after sorting and hybridized on Mouse Gene ST 2.0 Arrays. NPMc+ expression induced a total of 562 deregulations (322 up-regulations, FC>1.5; 240 down-regulations, FC<-1.5, FDR<0.1) while PML-RARα induced a total of 195 deregulations (117 up-regulations, FC>1.5; 78 down-regulations, FC<-1.5, FDR<0.1).

We ran a Gene Set Enrichment Analyses (GSEA) on the two pre-leukemic expression profiles. GSEA revealed that NPMc+ expression in LT-HSCs: (1) induces the expression of genes associated with HSCs and reduces the expression of genes associated with mature hematopoietic cells (Figure 9 A), (2) up-regulates genes involved in quiescence-related pathways such as TGFβ and TPO (Figure 9 B) and, (3) shows a marked correlation with the expression profiles from acute myeloid LSCs and human AML with mutated NPM1 (Figure 9 C).
Figure 9. NPMc+ expression in LT-HSCs enforces a stem cell transcriptional program promoting quiescence. GSEA plots demonstrating enrichment levels of indicated gene sets in NPMc+ LT-HSCs compared to WT LT-HSCs. A. GSEA plot correlating genes up-regulated in NPMc+ LT-HSCs with HSCs transcriptional program and genes down-regulated in NPMc+ LT-HSCs with mature hematopoietic cells expression profile. B. GSEA plot correlating genes up-regulated in NPMc+ LT-HSCs with TGFβ and TPO pathways. C. GSEA plot correlating genes down-regulated in NPMc+ LT-HSCs with genes down-regulated in NPM1 mutated AML, and genes up-regulated in NPMc+ LT-HSCs with genes enriched in HSCs and LSCs. Normalized enrichment score (NES) and false discovery rate (FDR) are indicated.
As expected, among the up-regulated genes, we also found the HoxA cluster and Meis1, genes involved in self-renewal maintenance and often deregulated in AML, including NPMc+ AML\textsuperscript{56}. Thus, GSEA data suggest that NPMc+ expression in LT-HSCs enforces a quiescent HSCs transcriptional program, which also characterizes LSCs. To further investigate molecular mechanisms related to quiescence regulation, we manually curated a list of genes directly involved in the maintenance of HSCs or LSCs quiescence, using data available in literature. Notably, we found many quiescence genes up-regulated by NPMc+ in LT-HSCs in our microarray data (Table 7).

<table>
<thead>
<tr>
<th>Gene symbol</th>
<th>FC</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gata2</td>
<td>2.1</td>
<td>\cite{27}</td>
</tr>
<tr>
<td>Angpt1</td>
<td>2</td>
<td>\cite{136}</td>
</tr>
<tr>
<td>Smad3</td>
<td>1.9</td>
<td>\cite{181}</td>
</tr>
<tr>
<td>Meis1</td>
<td>1.8</td>
<td>\cite{182}</td>
</tr>
<tr>
<td>Cdkn2c</td>
<td>1.7</td>
<td>\cite{183}</td>
</tr>
<tr>
<td>CD81</td>
<td>1.6</td>
<td>\cite{184}</td>
</tr>
<tr>
<td>Cbfa2t3</td>
<td>1.6</td>
<td>\cite{185}</td>
</tr>
<tr>
<td>Cdkn1a</td>
<td>1.6</td>
<td>\cite{21}</td>
</tr>
<tr>
<td>Tgfr2</td>
<td>1.6</td>
<td>\cite{181}</td>
</tr>
<tr>
<td>Egr1</td>
<td>1.6</td>
<td>\cite{186}</td>
</tr>
<tr>
<td>Cited2</td>
<td>1.4</td>
<td>\cite{29}</td>
</tr>
<tr>
<td>Tgfb1</td>
<td>1.4</td>
<td>\cite{181}</td>
</tr>
<tr>
<td>Mpl</td>
<td>1.4</td>
<td>\cite{6}</td>
</tr>
<tr>
<td>Pml</td>
<td>1.4</td>
<td>\cite{121}</td>
</tr>
<tr>
<td>Pbx1</td>
<td>1.4</td>
<td>\cite{187}</td>
</tr>
<tr>
<td>Terc</td>
<td>1.4</td>
<td>\cite{188}</td>
</tr>
<tr>
<td>Kit</td>
<td>1.3</td>
<td>\cite{189}</td>
</tr>
<tr>
<td>Gfi1</td>
<td>1.3</td>
<td>\cite{28}</td>
</tr>
<tr>
<td>Chd4</td>
<td>1.3</td>
<td>\cite{190}</td>
</tr>
<tr>
<td>Cebpa</td>
<td>1.3</td>
<td>\cite{191}</td>
</tr>
</tbody>
</table>

Table 7. NPMc+ expressing LT-HSCs up-regulated a set of quiescence positive regulators. For each quiescence gene is reported the FC of expression in NPMc+ LT-HSCs compared to WT LT-HSCs, based on microarray data, and the reference describing the role in quiescence regulation.
We validated by qPCR 15 out of 17 tested genes, including self-renewal genes (HoxA cluster and Meis1) and quiescence genes such as Gata2 and Gfi1 (Figure 10).

![Self-renewal genes](image1)

![Quiescence genes](image2)

**Figure 10. NPMc+ expression in LT-HSCs induces the up-regulation of self-renewal and quiescence genes.** qPCR analysis of WT and pre-leukemic LT-HSCs RNA for self-renewal (upper panel) and quiescence genes (lower panel) up-regulated by NPMc+. Results were normalized to the expression levels in WT LT-HSCs (** p<0.01).

In the other model, GSEA revealed that PML-RARα expressing LT-HSCs are characterized by: (1) induced expression of genes associated with HSCs and reduced expression of genes associated with mature hematopoietic cells transcriptional profiles\(^{179}\) (Fig. 11 A), (2) down-regulation of genes associated with proliferating HSCs\(^{192,193}\) (Fig. 11 B), (3) up-regulation of genes involved in RXR/RAR pathways or bound by PML-RARα\(^{194}\) (Fig. 11 C) and, (4) reduced expression of genes down-regulated in LSCs\(^{195}\) (Fig. 11 D).
Figure 11. PML-RARα expressing LT-HSCs are enriched in stem cells and quiescence signatures. GSEA plots demonstrating enrichment levels of indicated gene sets in PML-RARα LT-HSCs compared to WT LT-HSCs. A. GSEA plot correlating genes up-regulated in PML-RARα LT-HSCs with genes up-regulated in HSCs and genes down-regulated in PML-RARα LT-HSCs with genes expressed in mature hematopoietic cells. B. GSEA plot correlating genes down-regulated in PML-RARα LT-HSCs with genes down-regulated in quiescent HSCs and proliferating genes. C. GSEA plot correlating genes up-regulated in PML-RARα LT-HSCs with genes bound by PML-RARα and with the retinoic acid/vitamin D nuclear receptors pathway. D. GSEA plot correlating genes down-regulated in PML-RARα LT-HSCs with genes down-regulated in LSCs. Normalized enrichment score (NES) and false discovery rate (FDR) are indicated.
Moreover, PML-RARα up-regulated the expression of a different set of quiescence positive regulators, described in Table 8. Interestingly, although PML-RARα and NPMc+ are very different leukemic oncogenes, we found 6 quiescence genes commonly up-regulated by both oncogenes: Gata2, Cbfa2t3, Cdkn1a, Cdkn2c, Smad3 and Tgfbr2. We validated by qPCR the PML-RARα dependent up-regulation in LT-HSCs of all the quiescence genes we tested (Figure 12).

<table>
<thead>
<tr>
<th>Gene symbol</th>
<th>FC</th>
<th>Ref</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cdkn1a</td>
<td>2.1</td>
<td>21</td>
</tr>
<tr>
<td>Egr3</td>
<td>2.1</td>
<td>196</td>
</tr>
<tr>
<td>Hes1</td>
<td>1.7</td>
<td>197</td>
</tr>
<tr>
<td>Satb1</td>
<td>1.5</td>
<td>198</td>
</tr>
<tr>
<td>Tgfbr2</td>
<td>1.5</td>
<td>181</td>
</tr>
<tr>
<td>Junb</td>
<td>1.5</td>
<td>199</td>
</tr>
<tr>
<td>Fzd8</td>
<td>1.4</td>
<td>200</td>
</tr>
<tr>
<td>Cbfa2t3</td>
<td>1.4</td>
<td>185</td>
</tr>
<tr>
<td>Smad3</td>
<td>1.4</td>
<td>181</td>
</tr>
<tr>
<td>Atg7</td>
<td>1.4</td>
<td>201</td>
</tr>
<tr>
<td>G0s2</td>
<td>1.4</td>
<td>202</td>
</tr>
<tr>
<td>Cdkn2c</td>
<td>1.3</td>
<td>183</td>
</tr>
<tr>
<td>Gata2</td>
<td>1.3</td>
<td>27</td>
</tr>
</tbody>
</table>

**Table 8. PML-RARα LT-HSCs up-regulate a set of quiescence positive regulators.** For each gene is reported the FC of expression in PML-RARα LT-HSCs compared to WT LT-HSCs, based on microarray data, and the reference describing the role in quiescence regulation. Genes up-regulated in common with NPMC+ LT-HSCs are depicted in red.
Figure 12. PML-RARα expression in LT-HSCs up-regulates quiescence genes. qPCR analysis of WT and pre-leukemic LT-HSCs RNA for a set of quiescence genes up-regulated by PML-RARα. Results were normalized to the expression levels in WT LT-HSCs (** p<0.01).

8.3 NPMc+ and PML-RARα up-regulate a common set of quiescence genes in LT-HSCs

Strikingly, both NPMc+ and PML-RARα LT-HSCs gene expression profiles are significantly enriched in a set of genes preferentially expressed in adult quiescent HSCs, compared to more proliferating HSCs (i.e. fetal liver-HSCs and HSCs mobilized with 5-FU treatment) or ST-HSCs\textsuperscript{193} (Figure 13 A). Interestingly, among this signature, the genes accounting for the enrichment in both pre-leukemic transcriptional profiles showed a 30% overlap (p<0.01) (Figure 13 B).

Collectively, these data suggest that the expression of two unrelated oncogenes in LT-HSCs is sufficient to impose a transcriptional program that is highly specific for quiescent HSCs and it also correlates with LSCs/AML expression profiles. Thus, we tested the hypothesis that the enforcement of quiescence might be critical for the maintenance of the transformed clones during both the pre-leukemic and the leukemic phase by a reverse genetic approach. We selected, among genes up-regulated by NPMc+ and PML-RARα, ~100 genes involved
in stem cells quiescence regulation and we designed a shRNA library to perform \textit{in vivo} genetic screening.

**Figure 13.** NPMc+ and PML-RAR\(\alpha\) LT-HSCs up-regulate the same set of genes characteristic of quiescent HSCs. A. GSEA plots showing the enrichment of a quiescent HSCs signature in NPMc+ and PML-RAR\(\alpha\) LT-HSCs compared to WT LT-HSCs. B. Heatmap showing the most enriched quiescent HSCs genes up-regulated by NPMc+ and PML-RAR\(\alpha\), compared to WT LT-HSCs, and their overlap (p<0.012). Decreased gene expression is indicated by shades of blue; increased expression is indicated by shades of red.
8.4 The in vivo shRNA screening in NPMc+ and PML-RARα AML revealed clonality issues

We charged Cellecta Inc. with the design of a custom shRNA library cloned in the pRSI16 lentiviral vector. Lentiviral vectors allow transduction of both cycling and non-cycling cells, such as quiescent LSCs, and infected cells can be identified by the expression of the TagRFP reporter gene, also encoded by the pRSI16 backbone. The library used in the screen, from now on called M1 library, has a total complexity of 1,000 different shRNAs, targeting 92 genes and 4 controls, with 10 different hairpins for each gene. It is important to include control shRNAs (e.g. with an expected behavior with respect to the phenotype selected), such as shRNAs targeting essential genes, as controls of depletion, and shRNAs with no biological effect, as control of infection of a sufficient number of LSCs. In our library we inserted 20 hairpins targeting the essential genes Polr2b, Psma1 and Rpl30 and 20 shRNAs targeting the neutral gene Luciferase (LUC). Genes targeted in the screen are involved in diverse cellular process ranging from JAK/STAT pathway (Stat1, Stat3, Stat5a, Socs2), to TGFβ pathway (Tgfβ1, Tgfbr2, Jun, Smad3, Cited2), some of them are involved in cytokines signaling (Il18r1, Irf1, Irf3, Irf6, Angpt1, Kit, Tie1, Mpl), in metabolic processes (Abcb1b, Acox1, Adcy9, Adssl1, Txnrd1) or in transcriptional and epigenetic regulation (Pbx1, Gata2, Jun, Fos, Hoxa5, Kmt2a, Hdac5, Brd4). Importantly, each shRNA is univocally associated with a unique 22 bp DNA barcode, allowing identification and quantification of the corresponding hairpins by NGS.

To study the behavior of barcodes during the screening in vivo, and better characterize our model system, we designed a control library composed by 1,200 different DNA barcodes but not associated to any shRNA (thereafter 1.2k library). Therefore, the in vivo distribution of the barcodes is not affected by gene silencing but it only reflects the intrinsic functional heterogeneity of the blasts. We performed experiments in parallel using the two libraries. The direct comparison between the shRNAs and the non-targeting barcodes allows
identification of the shRNAs that are enriched or depleted during leukemia growth, as compared to the neutral selection of the barcodes.

The experimental strategy for shRNA screening is depicted in Figure 14. Transduction of murine NPMc+ or PML-RARα leukemic blasts, obtained from our mouse models, was performed in vitro by spinoculation, using concentrated viral supernatant at low multiplicity of infection (MOI=3). 24 hours after transduction, half of the cells were harvested as reference point (t0), while the remaining were intravenously injected in two recipient mice. For the NPMc+ leukemia samples, recipient mice were sublethally (5 Gy) irradiated 6-8 hours before transplantation to allow engraftment (that for this leukemia is dependent on prior irradiation).

![Figure 14. Strategy for shRNA screen in vivo.](image)

Mice have been checked weekly for leukemia development by monitoring the peripheral blood (PB). When the percentage of blasts in the PB was >80% (measured as percentage of CD45.2+ cells in C57 BL/6 Ly5.1 recipient mice), mice were sacrificed and spleen (SPL) and bone marrow were collected. Genomic DNA was purified and libraries for NGS were prepared according to Cellecta protocol (see Materials and Methods section 6.3.4). NGS data have been processed as described in detail in the Materials and Methods section 6.3.6. NGS data showed that in the reference samples, harvested 24 hours after transduction, all barcodes, of both the M1 and the 1.2k library were present, with a distribution range comprised within a 10-fold variance (Figure 15 A-B). This reflects the expected barcode.
distribution, based on how libraries have been synthetized by the supplier. Therefore, there were no unbalanced representation of shRNAs/barcodes in the cells used for the in vivo screen.

Figure 15. Barcode distribution is balanced in NPMc+ and PML-RARα reference samples (t0). A. Log_{10} frequency distribution of barcodes in reference samples infected with 1.2k library, 24 hours after transduction. B. Log_{10} frequency distribution of shRNAs in reference samples infected with M1 library, 24 hours after transduction. In NPMc+ P1E M1 ref sample is present one shRNA at very low frequency.

NGS analysis of the in vivo grown samples, instead, did not allow the identification of every barcode in the leukemic specimens. In experiments performed using the NPMc+ 414 AML, we were able to recover 86-96% and 85-92%, respectively, of shRNAs in the M1 screening and of the barcodes in the 1.2k screening. Moreover, their distribution showed a strong shift
towards the low frequencies due to a significant expansion of few barcodes, as shown in Figure 16 A-B.

**Figure 16.** Barcode frequency distribution show a strong shift upon AML growth. **A.** Log_{10} frequency distribution of .2k library barcodes in reference sample (Ref) and in two spleens (Spl E and Spl F) after leukemia growth. Spl E and Spl F were collected from two mice transplanted with the same blasts transduced with 1.2k barcodes library (same infection of Ref sample). **B.** Log_{10} frequency distribution of shRNAs in reference sample (Ref) and in two spleens (Spl A and Spl B) after leukemia growth. Spl A and Spl B were collected from two mice transplanted with the same blasts transduced with M1 shRNA library (same infection of Ref sample).
In particular, in sample Spl A, the 20 most represented shRNAs accounted for ~80% of the sample reads, while in Spl B the 20 most represented shRNAs accounted for more than 99% of the sample, with the first 2 shRNAs accounting for >87% (Figure 17 B). The most represented hairpins in the SPL samples were not the most abundant in the reference sample and, among the top 20 hairpins, only one was found in both replicates, reflecting the poor correlation between the two samples (r=0.23) and suggesting that the expansion of selected shRNA was not biologically driven (Figure 17 D). Accordingly, the same behavior was found in control screening with the 1.2k library, where the 20 most represented BCs in the two replicates, Spl E and Spl F, accounted for >90% of the samples (Figure 17 A). The barcode-identity correlation between the two 1.2k replicates was lower than in M1 screening (r=0.16), however in this case it was expected since barcodes should distribute randomly \textit{in vivo} (Figure 17 C). Unfortunately, we obtained similar results with another independent NPMc+ leukemia (NPMc+ P1E) and with one PML-RAR\(\alpha\) (PRKI 18) murine leukemia (not shown).
Figure 17. Few barcodes are highly expanded during in vivo screens with NPMc+ leukemia. A. Barcodes frequency distribution in 1.2k SPL samples. Spl E and Spl F were collected from two mice transplanted with the same blasts transduced with 1.2k barcodes library (same infection of Ref sample). B. shRNAs frequency distribution in M1 SPL samples. Spl A and Spl B were collected from two mice transplanted with the same blasts transduced with M1 shRNA library (same infection of Ref sample). *N.B. colors do not indicate barcodes identity. C. Pearson’s correlation between barcodes representation in Spl E and Spl F (replicates of 1.2k screening). D. Pearson’s correlation between shRNAs representation in Spl A and Spl B (replicates of M1 screening).

Together, these data suggest that individual LICs are extremely heterogeneous in their clonal expansion potential, with few LICs that posses a strong growth advantage over the others, and dramatically expanded in vivo after transplantation. From the perspective of our screening, the heterogeneous potential of LICs clonal expansion overcomes the selective pressure of shRNAs expression, thus preventing any meaningful bioinformatics analysis aimed at identifying biologically selected or counter-selected hairpins. Therefore, before
performing shRNA screening with AML samples in vivo, it is critical to evaluate the growth potential of individual LICs.

### 8.5 Clonal tracking experiments allow to study clonal growth in vivo

In order to further verify our hypothesis on clonal expansion and to set up a standard assay to evaluate in vivo clonal behavior of a given AML sample, we traced LICs in vivo using viral cellular insertion DNA barcoding and high-throughput sequencing. In particular, we performed clonal tracking experiments in which 1 million of leukemic blasts were transduced with a lentiviral library of DNA barcodes with a molecular complexity of 30 million, generated by the combination of 18+18 degenerated nucleotides sequences. In vitro transduction was performed at low multiplicity of infection (MOI=3) by spinoculation (see Materials and Methods section 6.3.3). The high library complexity and the low MOI used for the transduction assured integration of a unique DNA barcode into the cell genome (preliminary data on human AML, not shown) and identification of the cell progeny descending from each labelled cell. 24 hours after transduction, cells were intravenously injected into recipient mice and one aliquot has been frozen as reference (t0). Once mice developed leukemia, we harvested blasts from spleen and bone marrow to extract genomic DNA. Upon DNA library preparation, barcode sequences were identified by NGS (see Materials and Methods sections 6.3.4). For each sample, sequence reads were aligned to the reference library with no mismatch allowed and reads per barcode were normalized on total number of reads obtained. Reference samples were characterized by the presence of many barcodes at very low frequency (median 0.0003%, not shown), indicating that no barcode unbalance was present before transplantation.
8.6 Spike-in to set a threshold for clone identification

Due to the presence of several barcodes at low frequency, in order to establish a threshold for clone identification, we took advantage of a spike-in control. Prior to genomic DNA extraction from the *in vivo* grown samples, we added known quantities of NB4 cells (from 10 to 250,000 cells) each infected with a single different barcode of 18 nucleotides that can be amplified with the same PCR primers used for clonal tracking barcodes amplification. Therefore, during DNA library preparation for NGS, PCR product of samples containing the spike-in show two bands, one at the expected size of 267 bp and one smaller (249 bp) identifying barcodes in NB4 cells. After sample sequencing, we evaluated the relationship between the number of NB4 cells in the spike-in and the number of reads obtained for each barcode. As shown in Figure 18, we observed a linear relationship between the amount of cells harboring a specific barcode and the number of reads obtained for that barcode. Barcode associated to 10 cells did not retrieve any reads and barcode associated with 50 cells had a number of reads out of the linear range. However, considering only barcodes associated with higher amount of cells (>100 cells), we calculated a good linear correlation ($R^2 > 0.98$), indicating that PCR amplification does not saturate the relative frequency among different clones.
Figure 18. Spike-in control showed a linear relationship between the number of cells harboring a specific barcode and the NGS reads for the same barcode. In the table are reported the number of NB4 cells infected with a specific barcode and the number of reads retrieved by NGS in two independent NPMc+ AML samples. The graph in the lower panel show the linear relationship between number cells and NGS reads.

<table>
<thead>
<tr>
<th>Spike-in barcodes</th>
<th>Nr. of NB4 cells</th>
<th>NPMc+ 414 spl spike-in reads</th>
<th>NPMc+ P1E spl spike-in reads</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clone 6 TGACGTGTGTGTTGTGGT</td>
<td>10</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Clone 1 CAACACGTACTGGTGCA</td>
<td>50</td>
<td>24</td>
<td>34380</td>
</tr>
<tr>
<td>Clone 4 GTTGGTGTCACGTACCAA</td>
<td>100</td>
<td>10002</td>
<td>40964</td>
</tr>
<tr>
<td>Clone 10 ACTGCATGACGTGTCATG</td>
<td>1000</td>
<td>21546</td>
<td>80382</td>
</tr>
<tr>
<td>Clone 9 GTGTTGCATGCAACTGA</td>
<td>10000</td>
<td>116498</td>
<td>736260</td>
</tr>
<tr>
<td>Clone 7 TGGTTGAACATGCAACA</td>
<td>50000</td>
<td>483138</td>
<td>3149386</td>
</tr>
<tr>
<td>Clone 5 ACACACGTTCATGACAC</td>
<td>250000</td>
<td>2426862</td>
<td>14642890</td>
</tr>
</tbody>
</table>

8.7 Clonal tracking in vivo confirms clonal expansion during leukemia growth

Clonal tracking experiments on two NPMc+ AML samples showed that very few clones are highly expanded in vivo. In particular, in both NPMc+ leukemia, only 2 barcodes account for >90% of total reads (Figure 19). Interestingly, identity of the predominant barcodes in the spleen and the bone marrow of the same mouse was conserved (Figure 19 A).

These findings confirmed our hypothesis that among leukemic cells, few LICs have a strong growth advantage and are clonally selected in vivo. This, in turn, is associated with the presence of minor clones at very low frequency, below the threshold of sensitivity set by the spike-in.
Figure 19. Clonal tracking confirmed a strong clonal expansion during NPMc+ leukemia growth in vivo. Clonal tracking barcodes frequency distribution in two independent NPMc+ leukemia samples. A. Barcodes distribution in NPMc+ 414 SPL and BM. B. Barcodes NPMc+ P1E SPL. All barcodes found in the samples are depicted in the graph. *N.B. colors do indicate barcodes identity only between SPL and BM in NPMc+ 414 samples.

Assuming that only LICs are able to grow upon transplantation in recipient mice, the number of clonal barcodes retrieved in vivo can be used to measure LIC frequency, with the following formula:

\[
LIC \text{ freq} = \frac{\text{nr. transduced cells injected}}{\text{nr. of barcodes above the threshold}}
\]

However, in our experimental conditions, only a small proportion of clones were present at a frequency above the threshold set by the spike-in, due to the excessive clonal expansion of very few clones, therefore preventing a reliable evaluation of the LIC frequency in our AML samples (Table 9). Indeed, LICs with lower growth potential could not be scored in clonal representation because of the threshold set for clone identification.
### Table 9. LIC frequency calculated by clonal tracking is affected by the low number of barcodes above the threshold.

<table>
<thead>
<tr>
<th></th>
<th>NPMc+ 414 SPL</th>
<th>NPMc+ P1E SPL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total barcodes (BCs)</td>
<td>68</td>
<td>99</td>
</tr>
<tr>
<td>BCs considering spike-in threshold to 100 cells</td>
<td>5</td>
<td>2</td>
</tr>
<tr>
<td>Transduction efficiency</td>
<td>15%</td>
<td>14%</td>
</tr>
<tr>
<td>LIC frequency</td>
<td>1:30,000</td>
<td>1:70,000</td>
</tr>
</tbody>
</table>

In conclusion, two features of either NPMc+ or PML-RARa leukemias, namely relatively-low LIC frequency and high clonal heterogeneity of LICs, prevent the possibility of performing in vivo genetic screens, due to the low molecular complexity supported by both models.

### 8.8 The MLL-AF9 driven AML model

We then considered the possibility to use a different AML model. Notably, like human NPMc+ leukemia, human MLL-rearranged leukemia are characterized by the de-regulated expression of members of the HOX gene family\(^{203}\), which are involved both in HSCs in self-renewal regulation and AML development. Both NPMc+ and MLL fusion proteins have been shown to cooperate with the BET chromatin regulator BRD4 in the regulation of gene expression\(^{204,205}\). In NPMc+ leukemia, inhibition of BRD4 by NPM1 is lost, while, in MLL-rearranged AML, the fusion partner is often part of the super elongation complex (SEC) that recruits BRD4 to promote transcription. Recently, the SEC complex, MLL1 and the H3K79 methyltransferase DOT1L have been shown to control MEIS1 and HOX genes expression in NPMc+ AML\(^{206}\). Moreover, in AML patients, NPMc+ and DNMT3A mutations often co-occur while both alterations are mutually exclusive with MLL-rearrangements\(^{54,207}\), indicating that mutations in distinct epigenetic regulators share a convergent mechanism to induce self-renewal deregulation through MEIS1 and HOX genes overexpression. Therefore, based on the similarity to NPMc+ AML, and the fact that it has been previously used to
perform shRNA screen both \textit{in vitro} and \textit{in vivo}^{166,167,208}, we decided to perform our genetic screens using the MLL-AF9 (MA9) murine AML.

8.9 The MLL-AF9 pre-leukemic LSK gene expression profile is enriched in quiescent stem cell signatures

To analyze MA9-dependent transcription in defined hematopoietic subpopulation, we generated pre-leukemic mice, by transplanting MA9 transduced Lin- cells into lethally irradiated recipient mice. Mice were analyzed after 4 weeks from Lin- transplantation, to allow complete HSCs engraftment in the bone marrow niche. However, at this time point, the physiological organization of the bone marrow was totally lost (not shown), due to the ability of MA9 expression to induce accelerate leukemogenesis. Unfortunately, at 2 weeks after transplantation, control mice, transplanted with Lin- cells transduced with empty vector, had not yet completely reconstituted the bone marrow of the animals, while mice transplanted with MA9 Lin- cells showed a transformed-like phenotype (not shown). In conclusion, the MA9 behaves as a potent transforming oncogene in this model system, preventing appreciation of a pre-leukemic phase.

Thus, we decided to take advantage of previously reported transcriptional profiles of MA9 pre-leukemic LSK cells (Lin$, Sca1^+$ and Kit$^+$) derived from MA9 KI mice$^{209}$. The LSK compartment is enriched in stem cells and it is composed by LT-HSCs, ST-HSCs and MPPs. MA9 KI mice harbor the fusion gene in the endogenous Mll locus and are characterized by a prolonged pre-leukemic phase (~6 months) with myeloid proliferation and expansion of LSK cells, as compared to WT mice. Interestingly, this phenotype is similar to what we observed in our NPMc+ model where, upon transplantation of NPMc+ expressing BM-MNCs, we scored an expansion of the donor LSK compartment (unpublished data). In addition, the authors described a MA9-associated gene signature composed by 192 genes up-regulated in four pre-leukemic subpopulations (LSK, CMP, GMP and CLP).
Interestingly, NPMc+ and PML-RARα LT-HSCs gene expression profiles are enriched in this MA9 signature (Figure 20).

![Enrichment plots](image)

**Figure 20. Genes up-regulated by MA9 are enriched in NPMc+ and PML-RARα LT-HSCs gene expression profiles.**


Analysis of the MA9 LSK gene expression profile showed a strong up-regulation of genes directly involved in quiescence regulation such as Tie2 (FC=1.8) and its ligand Angpt1 (FC=1.4)\(^{136}\), Gimap5 (FC=1.7)\(^{210}\), Gata2 (FC=1.5)\(^{27}\), Tal1 (FC=1.3)\(^{211}\) and Pdk2 (FC=1.3)\(^{37}\).

8.10 Clonal tracking and LIC frequency evaluation in MLL-AF9 leukemia

To evaluate LIC frequency and the extent of LIC clonal heterogeneity in the MA9 leukemia, we performed in vivo clonal tracking experiments: one million MA9 blasts were infected with the 30 million barcodes library and transplanted in recipient mice. Upon leukemia development, we prepared sequencing libraries from genomic DNA extracted from the collected leukemic spleens. Samples were submitted to NGS and reads aligned to the reference library with no mismatches allowed. We retrieve 3,636 barcodes from one reference sample (Ref) and 159 different barcodes from one spleen (SPL) (Figure 21). Notably, the most represented barcode account for 14.8% of total reads, as compared to the
NPMc+ leukemia, where the most represented barcodes accounted for 50-80% of the sample.

![Clonal tracking barcodes distribution in reference (Ref) and spleen (SPL) samples. All barcodes found in the samples are depicted in the graph. *N.B. colors do not indicate barcodes identity.](image)

**Figure 21. MA9 leukemia grows in vivo without major clonal expansion.** Clonal tracking barcodes distribution in reference (Ref) and spleen (SPL) samples. All barcodes found in the samples are depicted in the graph. *N.B. colors do not indicate barcodes identity.

We identified 52 barcodes above the threshold, set by the spike-in (>100 cells). Considering the amount of injected MA9 blasts (1x10^6) and the transduction efficiency of 2%, measured by FACS analysis as percentage of TagRFP+ cells, we estimated a LIC frequency of 1 in 385 blasts. LIC frequency was also confirmed by Limiting Dilution Transplantation Assay (LDTA), the gold standard to evaluate LIC frequency in a given sample. Leukemic cells were transplanted into recipient mice at decreasing doses (from 500,000 to 100) and the proportion of mice that developed leukemia was used to calculate the number of self-renewing cells present in the sample. The results confirmed a high LIC frequency in MA9 leukemia model of 1:471 blasts (Table 10). Interestingly, in this AML model, LIC frequency estimation gave similar results with both the assay used, suggesting that all the LICs are able
to contribute to the growth of the leukemia in vivo and can be tracked under our experimental conditions.

<table>
<thead>
<tr>
<th>Cell dose MA9</th>
<th>Mice</th>
<th>Dead</th>
</tr>
</thead>
<tbody>
<tr>
<td>500000</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>100000</td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td>10000</td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td>1000</td>
<td>5</td>
<td>3</td>
</tr>
<tr>
<td>100</td>
<td>5</td>
<td>4</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Lower</th>
<th>Estimate</th>
<th>Upper</th>
</tr>
</thead>
<tbody>
<tr>
<td>1253</td>
<td>471</td>
<td>177</td>
</tr>
</tbody>
</table>

Table 10. MA9 LIC frequency calculation by limiting dilution. LDTA was performed by injecting decreasing numbers of MA9 into recipient mice (range 100-500000). The number of mice died of leukemia is indicated for each cell dose. LIC frequency was calculated using ELDA software.

In conclusion, analysis of LIC frequency and clonal heterogeneity suggest that MA9 leukemia can support the molecular diversity of our libraries during in vivo screenings.

8.11 MLL-AF9 shRNA screening in vivo

In vivo screens were performed as described for NPMc+ and PML-RARα leukemia. Briefly, MA9 blasts were transduced in vitro with the M1 or 1.2k libraries at MOI=3 using the spinoculation protocol (see Materials and Methods section 6.3.3). Based on the calculated LIC frequency, we determined the number of MA9 blasts to be transduced in order to cover the complexity of our shRNA library. Indeed, especially in drop-out screens, every shRNA should be ideally present in 5-10 LICs to score its effect and avoid false negative results. To this end, estimating a transduction efficiency of ~20%, we independently transduced 24x10^6 blasts for each replica. 24 hours after transduction, we collected half of the cells as reference points (t0) and used the other half for intravenously transplantation in recipient mice. A small
aliquot of cells was FACS analyzed 72 hours after transduction to evaluate infection efficiency, as percentage of TagRFP+ cells. Transduction efficiency was, on average, 17% and 22% for the M1 and 1.2k samples, respectively. We transplanted 6 mice for M1 and 4 mice for 1.2k screening. Three weeks post transplantation mice showed signs of leukemia development such as high percentage of donor cells and high WBC count in the peripheral blood, palpable splenomegaly and pale limbs. Therefore, we sacrificed all the animals and collected blasts from both the spleen and the bone marrow. All mice showed splenomegaly and high blasts infiltration in spleen and bone marrow, measured as percentage of CD45.1+ cells (MA9 blasts) on total cells retrieved from the same animals (C57 BL/6 J). We then proceed with genomic DNA extraction and library preparation for NGS (see Materials and Methods section 6.3.4). For each mouse we sequenced DNA from the spleen sample and the corresponding reference sample, for a total of 20 samples.

8.12 Identification of genes depleted during the in vivo screening

For each sample, barcodes sequencing reads were aligned to the corresponding reference library. Reference samples (Ref) had a uniform barcodes distribution comprised in around 10-fold variance for both libraries (Figure 22 A-C). Spleen samples (SPL), instead, showed a shift towards low frequencies for a number of barcodes, in both the M1 and in 1.2k library, much more evident in the M1 samples (Figure 22 B-D). However, this shift was not pronounced as the one observed in NPMc+ and PML-RARα screens, and we did not observe expansion of few barcodes, neither for M1 nor for 1.2k library. Indeed, the most abundant barcode accounted for <4% of total reads in each M1 sample, while it accounted for <0.5% of total reads in each 1.2k sample.
Figure 22. Barcode frequency distributions show a moderate shift during screening *in vivo*. A. Log_{10} barcodes distributions of 1.2k Ref samples. B. Log_{10} barcodes distributions of 1.2k SPL samples after *in vivo* screen. C. Log_{10} barcodes distributions of M1 Ref samples. D. Log_{10} barcodes distributions of M1 SPL samples after *in vivo* screen.
The correlation between M1 SPL samples was much higher than the one we obtained in the previous screens, with Pearson’s correlation coefficients ranging from 0.44÷0.55 (Figure 23).

<table>
<thead>
<tr>
<th></th>
<th>M1A</th>
<th>M1B</th>
<th>M1C</th>
<th>M1D</th>
<th>M1E</th>
<th>M1F</th>
</tr>
</thead>
<tbody>
<tr>
<td>M1A</td>
<td></td>
<td>0.55</td>
<td>0.53</td>
<td>0.48</td>
<td>0.51</td>
<td>0.52</td>
</tr>
<tr>
<td>M1B</td>
<td>0.55</td>
<td></td>
<td>0.53</td>
<td>0.47</td>
<td>0.52</td>
<td>0.54</td>
</tr>
<tr>
<td>M1C</td>
<td>0.53</td>
<td>0.53</td>
<td></td>
<td>0.44</td>
<td>0.49</td>
<td>0.52</td>
</tr>
<tr>
<td>M1D</td>
<td>0.48</td>
<td>0.47</td>
<td>0.44</td>
<td></td>
<td>0.47</td>
<td>0.48</td>
</tr>
<tr>
<td>M1E</td>
<td>0.51</td>
<td>0.52</td>
<td>0.49</td>
<td>0.47</td>
<td></td>
<td>0.49</td>
</tr>
<tr>
<td>M1F</td>
<td>0.52</td>
<td>0.54</td>
<td>0.52</td>
<td>0.48</td>
<td>0.49</td>
<td></td>
</tr>
</tbody>
</table>

**Figure 23.** shRNAs have a similar distribution in the 6 screening replicates. Pearson’s correlation of shRNAs abundance between each M1 SPL samples.

To increase the robustness of the screen, we analyzed 3 additional M1 samples (M1G, M1H and M1L) and one 1.2k, obtained from an independent *in vivo* screening, performed under identical experimental conditions. Samples were normalized and a multi-dimensional analysis was performed to visualize similarities among them. Interestingly, 2 out of the 3 additional M1 SPL samples, M1G and M1L, clustered together with the other M1 SPL samples, while all the reference samples clustered very close to each other (Figure 24 B). On the contrary, 1.2k SPL samples were less homogenously organized, with some of them clustering with the Ref samples (1.2k spl C, spl D, spl E and spl F), and other far away from each other (1.2k spl A and spl B) (Figure 24 A). Since the 1.2k barcodes should be devoided of any biological effect, they are expected to behave randomly *in vivo.*
Figure 24. Multi-dimensional scaling (MDS) plot show relationship between screening samples. A. 4 out of 6 1.2k Spl samples cluster with 1.2k Ref samples while two 1.2k Spl samples cluster far away from each other. B. Most of M1 Spl samples cluster together far from Ref samples.

We then performed bioinformatics analyses of the 9 replicates for the shRNA screening and the 5 replicates for the control screening. We developed two different pipelines for the identification of genes depleted or enriched during screenings in vivo. In the first pipeline, we analyzed the barcodes distribution in the SPL and the respective Ref sample calculating the fold change for each barcode (FC=SPL/t0). Distribution of FC showed that M1 samples have a clear bimodal distribution of shRNAs that is less evident in 1.2k samples (Figure 25).
Figure 25. shRNAs fold change distribution shows a number of depleted hairpins *in vivo*. The upper panel shows the log₂FC (SPL/t0) distributions of the barcodes in the 5 samples of 1.2k screening. The lower panel shows the log₂FC (SPL/t0) distributions of the shRNAs in the 9 samples of M1 screening.

We then used the “random” distribution of the 1.2k barcodes *in vivo* to define a threshold for the identification of significantly depleted/enriched shRNAs in M1 samples. To calculate an empirical pValue for each shRNA of each M1 sample, we computed an empirical cumulative distribution function (ECDF) summing up all 1.2k control sample distributions. We then aggregated these pValues among replicates for each shRNA using the Fisher’s Method, and obtained, for each shRNA, a FC, a pValue and a qValue. We identified 291 significantly depleted shRNAs and 223 significantly enriched shRNAs. Since for each gene were designed 10 hairpins, we established a threshold to define how many depleted/enriched shRNAs were sufficient to call a gene as depleted. To this end, we evaluated how many depleted shRNAs we would find by random picking 10 shRNAs among the others,
regardless the gene they target, for 1,000 times. This analysis revealed that if one gene has at least 5 of its hairpins depleted, we can define it as depleted with 95% confidence. We did the same for enrichment and we set the threshold to $\geq 4$ shRNAs to define a gene as enriched with 95% confidence. With this analysis we identified 15 significantly depleted and 14 significantly enriched genes.

For the second bioinformatics workflow, we took advantage of a previously published tool based on the EdgeR pipeline\textsuperscript{176}. Briefly, after sample normalization, we used the FC (SPL/t0) and pValue distributions of the 1.2k control samples to set a significance threshold to be applied to shRNA samples. We thus identified 167 significantly depleted shRNAs and 205 significantly enriched shRNAs. EdgeR package contains a gene set analysis-based tool, Roast, which allows to define if a gene is significantly depleted/enriched taking into consideration all the shRNAs targeting that gene. Roast analysis identified 19 significantly depleted and 18 significantly enriched genes. Among the depleted genes, in both analysis, we scored essential genes such as Rpl30 and Polr2b, and Brd4, already known to be critical for MA9 leukemia maintenance\textsuperscript{166} (Figure 26).

![Barcode plots](image)

**Figure 26. Essential genes are scored as depleted by Roast gene set analysis.** Barcode plots highlighting the rank of shRNAs targeting a specific gene relative to all other hairpins present in the M1 library.

We decided to start validation experiments by targeting genes in common between the two analyses which overlap for 10 genes (Figure 27).
8.13 Candidate genes validation

MA9 blasts were transduced with single shRNAs targeting each of the candidate gene, or with empty vector (EV) as control, and TagRFP+ cells were sorted 72 hours after transduction to obtain a pure population of infected blasts. RT-qPCR confirmed silencing of target genes at sorting time, compared to blasts infected with EV (Figure 28 A). To functionally test the effect of gene silencing in vitro, 500 sorted blasts were plated in methylcellulose (MC) cultures and colonies counted after one week. MA9 cells infected with shRNA targeting Brd4, Stat1 or Sytl4 were significantly less clonogenic, as compared to EV-transduced MA9 cells (Figure 28 B).
Figure 28. shRNA-mediated gene silencing reduces colony-forming efficiency in vitro. A. qPCR analysis of MA9 blasts infected with shRNAs targeting Brd4, Stat1 or Sytl4, compared to MA9 blasts infected with empty vector (EV), 72h post transduction. B. 500 MA9 TagRFP+ blasts infected with Brd4, Stat1 or Sytl4 shRNAs or EV were cultured in methylcellulose medium. The number of colonies scored after one week is shown (*p<0.05, **p<0.01).

Unexpectedly, upon two subsequent MC re-plating experiments, colonies quantification did not show the same differences scored in the first passage (not shown). However, when we counted only the TagRFP+ colonies (e.g. cells expressing the specific shRNAs) we scored a significant decrease in the Brd4, Stat1 and Sytl4 silenced samples, as compared to the control (Figure 29 A). Accordingly, upon serial passages, the percentage of TagRFP+ cells decreased in all shRNA samples, while it was maintained constant in the control blasts infected with EV (Figure 29 B). These data demonstrated that down-regulation of Brd4, Stat1 or Sytl4 was sufficient to decrease colony-forming efficiency of MA9 leukemia.

Figure 29. MA9 blasts infected with Brd4, Stat1 or Sytl4 shRNA are counter selected in vitro. A. 500 MA9 blasts from 1st plating in methylcellulose have been re-plated and TagRFP+ colonies only were counted one week later. B. At each re-plating in methylcellulose, the percentage of TagRFP+ cells was measured by FACS (*p<0.05, **p<0.01).
We next investigated the relevance of the candidate genes in leukemia maintenance *in vivo*. We intravenously injected $2 \times 10^5$ TagRFP+ sorted blasts infected with EV, Brd4, Stat1, Sytl4 or LUC (Luciferase) shRNA in sub-lethally irradiated recipient mice and we monitored leukemia development. Silencing of candidate genes significantly delayed leukemia onset, as compared to controls (median survival: EV=33 days, LUC=34 days, Brd4=51 days, Stat1=57 days and Sytl4=79 days) (Figure 30). EV and LUC mice succumbed of leukemia with the latency observed in other experiments, confirming that lentiviral infection did not alter the growth potential of MA9 leukemia *in vivo*.

![Figure 30. Brd4, Stat1 or Sytl4 down-regulation significantly delays MA9 leukemia burden.](image)

Brd4 requirement for MA9 AML has already been extensively described and, in line with Zuber’s work\textsuperscript{166}, we verified that blasts harboring Brd4-shRNA were depleted when leukemia appeared, by measuring the percentage of TagRFP+ blasts (CD45.1+) in PB, SPL and BM of leukemic mice (Figure 31 A). Interestingly, we obtained the same results for Stat1, suggesting that MA9 blasts expressing Stat1 shRNA were counter selected during leukemia growth *in vivo*. To test this hypothesis, we evaluated the mRNA level of Brd4 and Stat1 respectively, in leukemic cells collected when mice were sacrificed. As expected, outgrown leukemic blasts lost Brd4 or Stat1 silencing, with expression levels that were...
comparable to controls (Figure 31 B-C). Collectively, these data demonstrated that Stat1, likewise Brd4, is critical for MA9 growth in vivo.

Figure 31. MA9 blasts harboring Brd4 or Stat1 shRNA are counter selected during leukemia growth in vivo. Mice injected with MA9 blasts infected with Brd4 or Stat1 shRNA eventually died of leukemia. A. Evaluation of TagRFP+ cells in leukemic peripheral blood (PB), spleen (SPL) and bone marrow (BM) of mice injected with blasts infected with LUC, Brd4 or Stat1 shRNAs. B. qPCR analysis of Brd4 mRNA level in AML deriving from blasts infected with Brd4 shRNA, compared to blasts infected with LUC shRNA. C. qPCR analysis of Stat1 mRNA level in AML deriving from blasts infected with Stat1 shRNA, compared to blasts infected with LUC shRNA (**p<0.05).

The most striking delay in leukemia latency was observed in mice transplanted with blasts harboring Sytl4-shRNA (p=0.02, Mantel-Cox log-rank test). The Sytl4 (or Slp4) gene encodes for the Synaptogamin like protein 4, also known as Granuphilin-A, and it interacts with Rab27a GTPase, and important regulator of exosome release. Exosomes are small vesicles produced by cells in physiological conditions, which recently gained attention for their role in inter-tumoral trafficking of proteins, RNA and DNA. Therefore, we are
investigating this pathway by treating leukemic mice with GW4869, a sphingomyelinase (n-SMase) inhibitor which prevent exosome biogenesis (see Future plans).

We then started the validation of further 4 candidate genes identified as depleted during the screening in vivo: Socs2, Gfi1, Tie1 and Hoxa5. MA9 blasts were transduced and TagRFP+ cells sorted 72h after infection, as in the previous experiments. 500 sorted blasts were plated in MC cultures and colonies counted after one week. MA9 cells infected with shRNA targeting Gfi1, Tie1 or Hoxa5 were significantly less clonogenic, as compared to EV control, while blasts infected with Socs2 shRNA were not significantly different in clonogenic capacity (Figure 32 A). During subsequent passages in MC, blasts infected with Gfi1 shRNA were significantly counter selected, as shown in Figure 32 B by the percentage of TagRFP+ cells.

![Graph A](image1.png)

**Figure 32.** MA9 blasts infected with Gfi1, Tie1 or Hoxa5 shRNA have decreased clonogenic potential in MC. **A.** 500 MA9 TagRFP+ blasts infected with Socs2, Gfi1, Tie1 or Hoxa5 shRNAs or EV were cultured in methylcellulose medium. The number of colonies scored after one week is shown. **B.** 500 MA9 blasts from 1st plating in methylcellulose have been serially re-plated and percentage of TagRFP+ cells was scored at each passage by FACS (*p<0.05, **p<0.01).

However, RT-qPCR analysis at sorting time (i.e. 72h after transduction) revealed that only blasts infected with Socs2 shRNA showed a clear down-regulation of the target gene, while for Gfi1, Tie1 and Hoxa5, silencing was not effective at this time point (Figure 33).
Figure 33. Socs2 was efficiently down-regulated 72 hours after transduction. qPCR analysis of MA9 blasts infected with shRNAs targeting Socs2, Gfi1, Tie1 or Hoxa5 compared to MA9 blasts infected with empty vector (EV), 72h post transduction (**p<0.05).

Given these not conclusive results, we are repeating the experiments with different hairpins. Since three days of culture might not be sufficient to obtain a shRNAs effect on target genes, we analyzed gene silencing 5 days after transduction in TagRFP+ sorted cells. As shown in Figure 34, we were able to down-regulate Gfi1 and Tie1 compared to control, therefore we will proceed in performing both in vitro and vivo experiments using these two shRNAs.

Figure 34. Gfi1 and Tie1 were down-regulated 5 days after transduction. qPCR analysis of MA9 blasts infected with shRNAs targeting Gfi1 or Tie1 compared to MA9 blasts infected with empty vector (EV) (*p<0.05, **p<0.01).
8.14 Future plans

We have shown that quiescence genes that are up-regulated by relevant AML-associated oncogene in pre-leukemic cells are critical for the maintenance of leukemia growth. Our next goal is to demonstrate that the anti-leukemic effect of the selected quiescence genes is indeed due to their ability to regulate LSCs quiescence. Except for Gfi1, the role in quiescence of HSCs for the other candidate genes has not yet established. Therefore, we will investigate the effect of their silencing in WT and pre-leukemic HSCs by performing cell cycle analysis on stem cell compartment isolated from recipient mice after long term transplantation. Since our hypothesis arose from the biological effect of NPMc+ expression in LT-HSCs, we will especially study the impact of gene silencing in this pre-leukemic context.

Moreover, we will address if down-regulating our targets we will be able to score a diminished quiescence in the LSCs compartment of MLL-AF9 leukemia, where their immunophenotype has been extensively characterized. Unfortunately, the identification, by surface markers, of LSCs in murine NPMc+ and PML-RARɑ leukemia is not well established. Finally, in order to obtain indications regarding a possible therapeutic strategy, we will treat leukemic mice with combinations of chemotherapeutic agents and specific drugs targeting the quiescence genes/pathways identified in the screening.
9. Discussion

One of the major obstacles in AML eradication is the genomic and biological heterogeneity of the tumor. AML genomic complexity is a well described phenomenon characterized by the presence of multiple subclones within the leukemic bulk population\textsuperscript{48,49}. This intratumoral heterogeneity contributes to therapy failure and leukemia relapse, the major cause of death in AML patients. At biological level, AML are hierarchically organized and only LSCs, a minor population of the leukemic cells, are able to sustain tumor growth. Traditional chemo- and radiotherapies, which only target actively cycling cells, have limited effects on LSCs, mainly due to their quiescent state\textsuperscript{85}. Quiescence is an intrinsic property of HSCs and it closely linked to long-term self-renewal capacity, necessary for the maintenance of blood compartment throughout the whole lifetime of an individual. Similarly, LSCs are enriched in quiescent cells with the ability to self-renew and propagate the disease. Therefore, the development of therapeutic strategies aimed to target quiescent LSCs may have a profound impact on leukemia eradication.

In this work, we demonstrated that two non-related leukemic oncogenes, namely NPMc+ and PML-RAR\textsubscript{α}, are able to induce a common transcriptional program in HSCs. Specifically, a gene signature peculiar of quiescent stem cells is further enforced in the pre-leukemic HSCs expression profiles. Strikingly, a set of genes, already described to have a functional role in stem cells quiescence maintenance, was found to be up-regulated by NPMc+ and PML-RAR\textsubscript{α} during the pre-leukemic phase. In the same way, preliminary data on AML1-ETO pre-leukemic HSCs expression profile showed an enrichment in the same quiescent HSCs signature (not shown), indicating that the perturbations induced by different leukemic oncogenes converge on similar pathways. Consistently, a series of data obtained expressing different oncogenes in HSCs suggested that a tight regulation of cell cycle is functionally relevant for leukemia development\textsuperscript{107}. Moreover, Nras\textsuperscript{G12D}, a known leukemia initiating oncogene, has been described to exert a bimodal on HSCs\textsuperscript{213}. Nras\textsuperscript{G12D} expression is able to increase self-renewal potential in one subset of HSCs, maintaining their quiescent
state, while it increases the proliferation rate in another subset of HSCs. The author proposed a model where short lived but rapidly dividing \( \text{Nras}^{G12D} \) HSCs presumably outcompete wild-type HSCs and are replenished over time by the quiescent \( \text{Nras}^{G12D} \) HSCs, slowly recruited into cell cycle.

Our data suggested that the ability to enforce quiescence in HSCs is indeed a novel common feature of leukemia initiating oncogenes. Therefore, deeper characterization of the molecular mechanisms underlying oncogene-induced quiescence will shed light on functional relevant pathways in AML development, maintenance and response to therapies.

To assess if the quiescence-related genes induced in pre-leukemic phase are also relevant for leukemia maintenance, we investigated their role with \textit{in vivo} shRNA screening. Unfortunately, we found an unexpectedly marked expansion of few clones during NPMc+ and PML-RAR\( \alpha \) leukemia growth, confirmed by lentiviral clonal tracking experiments. Clonal expansion reflects the intrinsic biological heterogeneity within the LSCs compartment in terms of growth potential. So far, few studies have used cellular barcodes to study AML clonal dynamics and, consequently, the relationship between LSCs functional heterogeneity and leukemia clonal composition remains not clear. In a leukemia mouse model, tracking of barcoded cells, from cancer initiation to leukemia development, showed that clonal composition fluctuates during leukemogenesis eventually resulting in oligoclonal leukemia\textsuperscript{214}. Transplantation of human AML samples showed that xenografts are predominantly composed of few single genetically-defined subclones which are not the predominant in the primary sample\textsuperscript{80}. On the contrary, cellular barcoding of human B-ALL samples showed high polyclonal composition upon xenotransplantation in NSG mice. Interestingly, clones are asymmetrically distributed in mouse niches highlighting the influence of the environmental selective pressure\textsuperscript{155}. The major technical issue in clonal tracking experiments is cell transplantation in recipient mice which introduces by itself a strong selective proliferation pressure.
The strong clonal expansion we observed in NPMc+ and PML-RARα leukemia prevented any meaningful analysis of the screenings we performed. Therefore, we evaluated other AML models and we chose the MLL-AF9 driven leukemia, which showed a less prominent clonal growth in vivo. Interestingly, MLL-AF9 expression in normal stem cell compartment was able to up-regulate a set of quiescence genes, similarly to the other leukemia initiating oncogenes we examined. For these reasons, we performed the in vivo shRNA screening in this model, in parallel to a control screening with a non-targeting library composed by the same number of DNA barcodes. We implemented a novel strategy to analyze shRNA screening results based on the barcodes distribution of the non-targeting library in vivo. This library turned to be fundamental to account for the diverse proliferation capacity of LSCs upon in vivo transplantation. Two different bioinformatics pipelines allowed the identification of 10 significantly depleted genes, common to both the analyses. Among the targets we identified, we found Brd4, already described to play a critical role in MLL-AF9 leukemia maintenance. Polr2b and Rpl30, two essential genes we introduced in the screening as positive controls, scored as depleted in both analysis. Other depleted genes included Esr1, Gfi1, Hoxa5, Socs2, Stat1, Sytl4 and Tie1. In particular, Stat1 or Sytl4 down-regulation in MLL-AF9 blasts was sufficient to significantly delay leukemia onset in mice. Stat1, a transcription factor member of the STAT proteins family, is specifically activated by interferons and is involved in cell survival and pathogen response. Upon phosphorylation mediated by receptor associated kinases and Janus kinases (JAKs), STATs proteins form homo- or heterodimers and translocate to the nucleus where they regulate transcription of target genes. Stat1 is mainly described as a negative regulator of quiescence since INFα treatment is sufficient to trigger HSCs G0 exit, in a Stat1-dependent manner. Moreover, Stat1 depletion is sufficient to rescue the HSCs hyperproliferative caused by KO of Irgm1, a well known HSCs quiescence positive regulator. On the other side, Stat1 can induce cell growth arrest by inducing the expression of p21 and p27 and down-regulating cMyc in U937 cells. Interestingly, in hematological malignancies models, Stat1 has been described to
play a role in LSCs expansion\textsuperscript{218}, in immunological surveillance escaping\textsuperscript{219} and in therapy resistance\textsuperscript{220}. Moreover, the constitutive activation of STAT proteins has been demonstrated in leukemic cell lines and AML blasts\textsuperscript{221,222}, laying the basis for several clinical trials with JAK/STAT inhibitors.

Furthermore, we showed that down-regulation of Sytl4 in MLL-AF9 blasts is sufficient to decrease colony-forming efficiency \textit{in vitro} and significantly delay leukemia growth \textit{in vivo}. Sytl4 interacts with Rab27a, a key regulator of exosomes release. Impaired exosome maturation has already been linked to HSCs exit from quiescence. Indeed, HSCs release extracellular vesicles containing cytokines such as Angptl2 and TPO which are necessary to maintain HSCs activity through an autocrine signaling effect\textsuperscript{223}. AML patients are characterized by high plasma levels of blasts-derived exosomes which decrease after induction therapy, mirroring blasts reduction in the bone marrow. Moreover, patients achieving long-term remission typically have exosomes plasma levels comparable to healthy individuals, suggesting that this parameter might have prognostic significance\textsuperscript{224}. Vesicles content partially depends on the parent cell type and, in particular, AML exosomes are important for the crosstalk between leukemic cells and the environment by modulating immune response, blast survival, angiogenesis and resistance to therapies\textsuperscript{225}. Strategies to specifically block exosome release in AML need further mechanistic studies to avoid indiscriminate interfering with physiological processes.

As discuss in the future plans, our main goal is now to link the effect of the identified quiescence genes on leukemia growth to a direct role in quiescence maintenance. To this aim we will study both the effect of gene silencing in normal and pre-leukemic LT-HSCs in homeostatic conditions, and the extent of LSCs G0 exit, wherever they are immunophenotypically defined. To overcome this limitation, we will exploit functional assays for the identification of LSCs such as the H2B-GFP lentiviral labelling tool\textsuperscript{226}. Leukemic blasts transduced with lentiviral Tet-Off H2B-GFP vector can be treated with
doxycycline to dilute the GFP signal upon cell divisions. With this system we can functionally isolate slow cycling LSCs in the fraction of GFP label-retaining cells. The following step will be to investigate if the mechanism is conserved in human samples. To this purpose, we can take advantage of the large cohort of AML xenografts already available in the lab. Ultimately, we hope to discover new therapeutic targets able to induce LSCs to proliferate becoming sensitive to standard chemotherapy strategies. Indeed, the exclusive target of LSCs may be insufficient to obtain effective leukemia cure because of the hyperproliferation of the bulk population. On the contrary, a biological meaningful combination of therapies directed against both LSCs and proliferating blasts, would allow to reach a definitive leukemia eradication.
10. References


65. Ronchini, C. et al. PML-RARA-associated cooperating mutations belong to...


91. Taussig, D. C. et al. Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34(-) fraction.


97. Lagadinou, E. D. et al. BCL-2 inhibition targets oxidative phosphorylation


149. Wunderlich, M. et al. AML xenograft efficiency is significantly improved in NOD/SCID-IL2RG mice constitutively expressing human SCF, GM-CSF and...
101


Li, Q. *et al.* Oncogenic Nras has bimodal effects on stem cells that sustainably


